KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
के लिए फिर से शुरू Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: आँकड़ों को प्रभावित करें
रिपोर्ट चलाएं
| Concept | World rank |
|---|---|
| capilia adeno | #1 |
| cases severe conjunctivitis | #1 |
| talymus | #1 |
| dscg fml | #1 |
| tacrolimus ophthalmic suspension | #1 |
| scores hyperemia | #1 |
| adeno eye | #1 |
| conjunctival fibroblasts production | #1 |
| 01 tacrolimus eye | #1 |
| 12 patients akc | #1 |
| cedrus conjunctivitis | #1 |
| artificial tears positive | #1 |
| eyewash solutions | #1 |
| suspension treating | #1 |
| atopic keratoconjunctivitis | #1 |
| eyewash solution | #1 |
| postoperative conjunctivitis | #1 |
| commercial eyewash | #1 |
| iop akc | #1 |
| patients capilia | #1 |
| eyebon | #1 |
| bf concomitantly | #1 |
| washing allergens | #1 |
| initiating tacrolimus | #1 |
| epithelial pge2 | #1 |
| keratoconjunctivitis male | #1 |
| fml administered | #1 |
| tears conjunctival fibroblasts | #1 |
| hyperemia pain | #1 |
| objective findings conclusions | #1 |
| allergic conjunctivitis drop | #1 |
| bf fml | #1 |
| scleritis tacrolimus | #1 |
| eye fml | #1 |
| akc patients | #1 |
| therapy levocabastine | #1 |
| allergenmediated conjunctivitis | #1 |
| patients akc | #1 |
| pge2 human conjunctival | #1 |
| eye itching | #1 |
| akc treatment | #1 |
| efficacy fml | #1 |
| positivity rate allerwatch | #1 |
| allergic postoperative | #1 |
| radioimmunoassay il4 | #1 |
| bromfenac sodium treatment | #1 |
| tacrolimus eye treatment | #1 |
| sodium ophthalmic solution | #1 |
| keratoconjunctivitis background | #1 |
| conjunctivitis japanese | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| commercial washing solution | #1 |
| tears allergic patients | #1 |
| allerwatch positivity rate | #1 |
| keratocytes tnfα | #1 |
| tacrolimus tears | #1 |
| antagonists child conjunctivitis | #1 |
| compared fluorometholone | #1 |
| solution ocular | #1 |
| tranilast dexamethasone | #1 |
| immunocytochemical study rtpcr | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| epithelium disorders | #1 |
| test capilia | #1 |
| ketotifen fumarate dexamethasone | #1 |
| levocabastine artificial | #1 |
| allergic conjunctivitis | #1 |
| 3 months signs | #1 |
| signs palpebral | #1 |
| patients allergic conjunctivitis | #1 |
| allerwatch higher | #1 |
| concomitant bf | #1 |
| primary human conjunctival | #1 |
| severity objective signs | #1 |
| akc compared | #1 |
| akc tear | #1 |
| bromfenac sodium bf | #1 |
| conjunctival fibroblasts | #1 |
| satisfaction suspensions | #1 |
| adenovirus capilia | #1 |
| adverse events scores | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| experience 01 | #1 |
| tears allergic | #1 |
| tacrolimus eye | #1 |
| tacrolimus eye drops | #1 |
| eye wash | #1 |
| fml patients | #1 |
| instillation bromfenac | #1 |
| clinical signs akc | #1 |
| dha western blotting | #1 |
| selective chemotactic effects | #1 |
| bak epithelium | #1 |
| exacerbation vkc | #1 |
| conjunctivitis aims | #1 |
| subjective ocular symptoms | #1 |
| eye allerwatch | #1 |
| samples allergic conjunctivitis | #1 |
| improvement combinedtreatment | #1 |
| conjunctivitis enrolled | #1 |
| conclusions objective assessments | #1 |
| levocabastine artificial tears | #1 |
| accuracy conjunctivitis | #1 |
| conjunctivitis conjunctival | #1 |
| hundredandseventy eyes | #1 |
| 01 ophthalmic solution | #1 |
| pcr eotaxin1 | #1 |
| eyewash solutions bak | #1 |
| eotaxin1 production | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| corneal epithelium disorders | #1 |
| allergic tranilast | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| ded anti | #1 |
| tacrolimus ophthalmic solution | #1 |
| allergic enzyme | #1 |
| keratoconjunctivitis akc | #1 |
| sodium bf | #1 |
| cd3 cd4bearing cells | #1 |
| tacrolimus eye drop | #1 |
| systemic control pain | #1 |
| allergic docosahexaenoic | #1 |
| dscg symptoms | #1 |
| vkc akc | #1 |
| dscg bf | #1 |
| patients atopic keratoconjunctivitis | #1 |
| efficacy bromfenac sodium | #1 |
| commercial eyewash solutions | #1 |
| dha il4 | #1 |
| instillation symptoms | #1 |
| rapid ophthalmic | #1 |
| 0001 allerwatch | #1 |
| vkc april | #1 |
| characterized conjunctival | #1 |
| akc vernal | #1 |
| ocular allergic diseases | #1 |
| eyewash solution bak | #1 |
| conjunctival cedar | #1 |
| 10 objective signs | #1 |
| incubated interleukin | #1 |
| allergens levocabastine | #1 |
| vkc conclusions | #1 |
| dscg 005 | #1 |
| il4 tear | #1 |
| vkc cases | #1 |
| prostaglandin tears | #1 |
| conjunctivitis including | #1 |
| stat6results | #1 |
| itchy sensation | #1 |
| sodium allergic | #1 |
| include conjunctival | #1 |
| production conjunctival fibroblasts | #1 |
| cox2 conjunctival | #1 |
| eyewash | #1 |
| diseases tear | #1 |
| keratoconjunctivitis vernal | #1 |
| atopic keratoconjunctivitis akc | #1 |
| allergic corneal | #1 |
| tacrolimus ophthalmic | #1 |
| bromfenac sodium | #1 |
| allergic conjunctivitis efficacy | #1 |
| adult cedrus conjunctivitis | #1 |
| akc methods | #1 |
| akc | #1 |
| severe binocular conjunctivitis | #1 |
| fourgraded severity | #1 |
| release inhibitor purpose | #1 |
| allerwatch tests | #1 |
| initiation tacrolimus treatment | #1 |
| suppressing pge2 production | #1 |
| akc allergic | #1 |
| action child conjunctivitis | #1 |
| ige allerwatch | #1 |
| il4 tranilast | #1 |
| solution allergic | #1 |
| akc vkc | #1 |
| severe akc | #1 |
| eyebon eye | #1 |
| itching levocabastine | #1 |
| fml dscg | #1 |
| conjunctivitis helper | #1 |
| production tranilast | #1 |
| binocular conjunctivitis | #1 |
| bak epithelium disorders | #1 |
| conjunctivitis concomitantly | #1 |
| tranilast eotaxin1 | #1 |
| fml 002 | #1 |
| nsaids systemic control | #1 |
| production ketotifen fumarate | #1 |
| il4 causing | #1 |
| rate allerwatch | #1 |
| allerwatch diagnostic accuracy | #1 |
| bromobenzenes conjunctivitis | #1 |
| conjunctivitis seasonal | #1 |
| selected fml | #1 |
| inhibition eotaxin1 | #1 |
| higher capilia | #1 |
| child conjunctivitis | #1 |
| severe conjunctivitis eyes | #1 |
| eye surface years | #1 |
| fumarate dexamethasone | #1 |
| higher akc | #1 |
| fluorometholone 002 | #1 |
| rsv conjunctival | #1 |
| conjunctivitis treated | #1 |
| drops elicited | #1 |
| patients severe conjunctivitis | #1 |
| drop levocabastine | #1 |
| akc administration | #1 |
| capilia adeno eye | #1 |
| tranilast production | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| corneal recurrences | #2 |
| fluorescein conjunctival injection | #2 |
| allergic endophthalmitis | #2 |
| cedrus conjunctiva | #2 |
| tacrolimus topical | #2 |
| immunoregulatory effects study | #2 |
| papilla accompanied | #2 |
| treatment shield ulcer | #2 |
| neutrophils brush | #2 |
| akc patients correlation | #2 |
| total clinical signs | #2 |
| corneal damage height | #2 |
| ophthalmic nsaid | #2 |
| brush cytology patients | #2 |
| epitheliopathy refractory | #2 |
| betamethasone glaucoma | #2 |
| 2helper cell | #2 |
| mucous discharge severity | #2 |
| papillae mucous discharge | #2 |
| scores tacrolimus | #2 |
| corneal epithelial signs | #2 |
| conjunctiva bulbar | #2 |
| adjuvant fluorometholone 95 | #2 |
| cornea grading | #2 |
| dryness scores | #2 |
| diabetic patients ono2235 | #2 |
| eyewash 005 | #2 |
| solutions japan | #2 |
| steroid metaregression | #2 |
| allergic conjunctivitis levocabastine | #2 |
| study designopen cohort | #2 |
| giant papillae formation | #2 |
| treatment tear | #2 |
| epitheliopathy patients | #2 |
| rhodanine rose | #2 |
| lower conjunctival sacs | #2 |
| akc sac patients | #2 |
| effects tacrolimus | #2 |
| corneal lesions regrowth | #2 |
| folliculosis papillae | #2 |
| lesions allergic | #2 |
| conjunctivitis representative | #2 |
| methods thirtysix patients | #2 |
| corneal findings | #2 |
| eosinophils corneal damage | #2 |
| allergy accompanied | #2 |
| scores papillary | #2 |
| complain foreign | #2 |
| mmc 7 eyes | #2 |
| eyelid atopic | #2 |
| papillae limbus | #2 |
| elevation tacrolimus | #2 |
| deqs tear | #2 |
| extents corneal | #2 |
| corneal epitheliopathy | #2 |
| severity eyelid | #2 |
| severity corneal lesions | #2 |
| tacrolimus detection | #2 |
| swelling folliculosis | #2 |
| factor vkc | #2 |
| steroids epitheliopathy | #2 |
| eyelid skin elasticity | #2 |
| placebo noninferiority | #2 |
| corneal ulcers patients | #2 |
| conjunctival injection reduction | #2 |
| sodium ophthalmic | #2 |
| tears akc | #2 |
| atopic diagnostic techniques | #2 |
| simple papillary resection | #2 |
| conjunctivitis proliferative | #2 |
| keratoconjunctivitis age | #2 |
| plaques 791 | #2 |
| nonpreserved eyewash solution | #2 |
| suspension lactoferrin | #2 |
| defined conjunctival | #2 |
| akc aureus | #2 |
| talymus akc | #2 |
| corneal lesions | #2 |
| unpaired ttest talymus | #2 |
| refractory allergic | #2 |
| simple resection regrowth | #2 |
| total signs symptoms | #2 |
| diagnosis ensured | #2 |
| bromfenac ophthalmic solution | #2 |
| serum allergic parameters | #2 |
| dermatitis remission | #2 |
| conjunctival corneal cells | #2 |
| signs decreased | #2 |
| blepharitis ceramides | #2 |
| vkc 5 | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| tacrolimus 1 month | #2 |
| corneal epitheliopathy score | #2 |
| lacrimation objective | #2 |
| correlation neutrophils | #2 |
| height papillae | #2 |
| elasticity severity | #2 |
| vkc japan | #2 |
| tacrolimus detection limit | #2 |
| papillae akc | #2 |
| atopic blepharitis | #2 |
| oral aldose | #2 |
| eyes betamethasone | #2 |
| effects topical tacrolimus | #2 |
| epinastine superiority | #2 |
| hyperemia lacrimation | #2 |
| diathesis subjective | #2 |
| ocular surface mucin | #2 |
| conjunctivitis epitheliopathy | #2 |
| baseline papillae | #2 |
| asthma heart diseases | #2 |
| elasticity eyelid | #2 |
| based papillae | #2 |
| normal blinking patients | #2 |
| sem575 clinical | #2 |
| corneal temperature patients | #2 |
| conjunctiva papillary | #2 |
| score topical | #2 |
| sem575 | #2 |
| sodium bromfenac | #2 |
| drop concomitantly | #2 |
| 18 akc | #2 |
| test papillae | #2 |
| oral ari ono2235 | #2 |
| air pollutants prevalence | #2 |
| tear film layer | #2 |
| csa akc | #2 |
| prevalence akc | #2 |
| conjunctivitis 10 | #2 |
| aureussecreted enterotoxins | #2 |
| epitheliopathy score | #2 |
| administered elf | #2 |
| cytodiagnosis dermatitis | #2 |
| ulcer complain | #2 |
| oral ari administration | #2 |
| nonwash | #2 |
| efficacy severe akc | #2 |
| evaluate superiority | #2 |
| resolution thermography | #2 |
| female humans akc | #2 |
| conjunctivitis purpose | #2 |
| concomitantly abovementioned | #2 |
| japan topical | #2 |
| edema height | #2 |
| akc levels | #2 |
| bovine entericcoated lactoferrin | #2 |
| olopatadine visit | #2 |
| improvement corneal fluorescein | #2 |
| tacrolimus shield | #2 |
| papillary excision | #2 |
| keratoconjunctivitis corneal | #2 |
| ari ocular | #2 |
| formation palpebral | #2 |
| decrease corneal temperature | #2 |
| mmc aided | #2 |
| mucin analyzed | #2 |
| patients shield ulcers | #2 |
| 001 brush | #2 |
| tarsal brush | #2 |
| lid skin | #2 |
| akc adult | #2 |
| 95 adjuvant betamethasone | #2 |
| treatment ecp concentrations | #2 |
| akc treated | #2 |
| month eyewash | #2 |
| tacrolimus tonometry | #2 |
| adjustments epitheliopathy | #2 |
| production specular | #2 |
| drops refractory | #2 |
| tacrolimus published data | #2 |
| superiority epinastine | #2 |
| reported eotaxin | #2 |
| epitheliopathy shield | #2 |
| corneal complications height | #2 |
| inflammatory child child | #2 |
| drop steroid | #2 |
| iop topical steroids | #2 |
| treated bromfenac | #2 |
| proliferative called | #2 |
| epitheliopathy steroids | #2 |
| papillae preventing | #2 |
| severity corneal damage | #2 |
| skin elasticity patients | #2 |
| treatment atopic blepharitis | #2 |
| akc young adult | #2 |
| period rhodanine | #2 |
| cobblestonelike papillae | #2 |
| adjuvant fluorometholone | #2 |
| epinastine ophthalmic solution | #2 |
| premedication combined | #2 |
| akc allergic diagnosis | #2 |
| japan akc | #2 |
| eyelid elasticity | #2 |
| limbal swelling | #2 |
| ecp levels akc | #2 |
| akc 6 | #2 |
| bromfenac effective | #2 |
| ceramide gel application | #2 |
| conjunctival injection edema | #2 |
| 062 tear | #2 |
| cac test | #2 |
| ensured proving | #2 |
| cutometer sem575 | #2 |
| noninferiority olopatadine | #2 |
| ketotifen dexamethasone | #2 |
| tacrolimus iop | #2 |
| correlation eosinophils | #2 |
| bromfenac sodium bromfenac | #2 |
| corneal damage patients | #2 |
| treatment total signs | #2 |
| disease antiallergic | #2 |
| lactoferrin 01 | #2 |
| akc 10 | #2 |
| environmental studies prevalence | #2 |
| epinastine 15 minutes | #2 |
| patients shield | #2 |
| objective signs baseline | #2 |
| akc adolescent | #2 |
| topical antiallergic agents | #2 |
| adjustments epitheliopathy score | #2 |
| topical tacrolimus combination | #2 |
| administered elf bovine | #2 |
| patients corneal ulcers | #2 |
| conjunctivitis adolescent | #2 |
| edema corneal damage | #2 |
| score adjustments | #2 |
| suspension talymus | #2 |
| adjuvant betamethasone | #2 |
| papillae severe | #2 |
| papillary formation | #2 |
| conventional antiallergic drugs | #2 |
| administration specular | #2 |
| control subjects eyes | #2 |
| tears thiazolidines | #2 |
| formation akc | #2 |
| patients tacrolimus eye | #2 |
| excision cobblestone | #2 |
| including akc | #2 |
| accompanied subjective | #2 |
| regrowth 7 eyes | #2 |
| benzophenones bromobenzenes | #2 |
| endpoint itching scale | #2 |
| brush cytology samples | #2 |
| bovine placebo | #2 |
| severity corneal complications | #2 |
| drops conjunctival | #2 |
| eyes 824 | #2 |
| conjunctivitis retrospective | #2 |
| patients severe akc | #2 |
| akc 1 | #2 |
| lessen steroid | #2 |
| allergic conjunctivitis ige | #2 |
| regrowth papillae | #2 |
| improvement vital staining | #2 |
| ecp severity markers | #2 |
| conjunctivitis condition | #2 |
| severe allergic conjunctivitis | #2 |
| conjunctiva atopic | #2 |
| pollutants prevalence | #2 |
| correlation fluorescein | #2 |
| giant papillary formation | #2 |
| aided papillary | #2 |
| metaregression analysis glaucoma | #2 |
| selected bf | #2 |
| epitheliopathy corneal | #2 |
| detected akc | #2 |
| neutrophils corneal damage | #2 |
| eyelid atopic dermatitis | #2 |
| shield ulcers patients | #2 |
| muc16 immunohistochemistry | #2 |
| japan topical tacrolimus | #2 |
| recurrence corneal complications | #2 |
| signs blood concentration | #2 |
| oral ari | #2 |
| tacrolimus 12 weeks | #2 |
| conclusions bromfenac | #2 |
| allergic conjunctivitis akc | #2 |
| representative subjective | #2 |
| sac healthy | #2 |
| conjunctival findings severity | #2 |
| 1 month tacrolimus | #2 |
| olopatadine cedar | #2 |
| olopatadine ocular | #2 |
| largescale study protocol | #2 |
| recurrence corneal lesions | #2 |
| drops hyperemia | #2 |
| pge2 tears | #2 |
| excision cobblestonelike papillae | #2 |
| allergic diagnosis | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| tear ige correlation | #2 |
| seasonal allergic conjunctivitis | #2 |
| tacrolimus lessen | #2 |
| akc 10 eyes | #2 |
| post cataract surgery | #2 |
| solution epinastine | #2 |
| sem575 quantitatively | #2 |
| akc confocal microscopy | #3 |
| healed amniotic | #3 |
| superior limbic portion | #3 |
| papillae morphometric | #3 |
| allergic patients conjunctivitis | #3 |
| superficial cells conjunctiva | #3 |
| induced inflammation lenses | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| dscg administration | #3 |
| lower muc5ac | #3 |
| 5ac mrna | #3 |
| underwent staining | #3 |
| tears treatment | #3 |
| titers ade | #3 |
| hydrochloride 01 | #3 |
| topical cyclosporine 01 | #3 |
| papillary resection | #3 |
| akc dyes humans | #3 |
| 5ac brush | #3 |
| pilocarpine visante | #3 |
| tear periostin comorbidities | #3 |
| par2 benzamidines blotting | #3 |
| hyperemia allergic | #3 |
| elisa histamine | #3 |
| lamp device | #3 |
| tmh measurement | #3 |
| technique 2 eyes | #3 |
| papillae upper | #3 |
| insufficient tear | #3 |
| ari corneal | #3 |
| tear periostin | #3 |
| diseases acds | #3 |
| fibers lnfs | #3 |
| dfna diclofenac epithelium | #3 |
| benzamidine par2 | #3 |
| existence par2 mrna | #3 |
| vkc relevant factor | #3 |
| ulcers plaques | #3 |
| injections keratoconjunctivitis | #3 |
| aged biological dressings | #3 |
| surgery dfna | #3 |
| scored global | #3 |
| 12 akc patients | #3 |
| local tear deficiency | #3 |
| cell flare count | #3 |
| differences dfna | #3 |
| ulcer akc | #3 |
| nbs subbasal | #3 |
| weekly average values | #3 |
| drops treat | #3 |
| patching case | #3 |
| reaction conjunctiva | #3 |
| 3 sjögrens syndrome | #3 |
| ulcers eyes | #3 |
| il1beta th2 | #3 |
| commercial washing | #3 |
| interleukin4 histamine | #3 |
| interleukin4 tacrolimus | #3 |
| proving type | #3 |
| conjunctival fibroblasts tryptase | #3 |
| association outpatient attendance | #3 |
| aged elisa | #3 |
| mmcaided papillary resection | #3 |
| ophthalmic solution nsaid | #3 |
| vkc exacerbation | #3 |
| conjunctivitis benzamidines | #3 |
| vkc fibronectin | #3 |
| outpatient attendance july | #3 |
| oct graticule | #3 |
| normal controls collagens | #3 |
| glaucoma amniotic | #3 |
| prophylaxis conjunctival | #3 |
| sensitivity tear | #3 |
| efficacy bromfenac | #3 |
| increased comfort | #3 |
| fluorescein glycyrrhizic | #3 |
| scale tmh | #3 |
| conjunctivitis allergic | #3 |
| akc atopic dermatitis | #3 |
| diclofenac epithelium | #3 |
| akc comorbidities | #3 |
| techniques conjunctivitis | #3 |
| treatment skin elasticity | #3 |
| production conjunctival | #3 |
| akc higher | #3 |
| conjunctival disease | #3 |
| patients tmh measurements | #3 |
| lnfs nbs | #3 |
| uncontrollable glaucoma | #3 |
| vivo corneal akc | #3 |
| fluorescein scale | #3 |
| cooling cataract | #3 |
| 005 collagens | #3 |
| vkc levels | #3 |
| rose bengal akc | #3 |
| 005 ophthalmic solution | #3 |
| muc1 brush cytology | #3 |
| histamine cedar | #3 |
| akc tear periostin | #3 |
| ssdry | #3 |
| flare metry | #3 |
| treatment strip meniscometry | #3 |
| akc serum periostin | #3 |
| antieaigg | #3 |
| tear il13 | #3 |
| vkc differences | #3 |
| dfna control | #3 |
| histamine superficial cells | #3 |
| akc higher muc1 | #3 |
| aureus akc patients | #3 |
| eye washing | #3 |
| corneal complications1 | #3 |
| underwent periodic | #3 |
| il1beta th2 cytokines | #3 |
| postsurgical conjunctivitis | #3 |
| metry dfna | #3 |
| fibronectin normal controls | #3 |
| decline corneal | #3 |
| formation vernal | #3 |
| 21 akc | #3 |
| papillary regrowth | #3 |
| allergic postsurgical | #3 |
| allergic corneal ulcer | #3 |
| prospectively diclofenac | #3 |
| temperature evaluate | #3 |
| operation eye | #3 |
| dramatic healing | #3 |
| allerwatch | #3 |
| insensible administration insensible | #3 |
| infrared radiation thermography | #3 |
| 01 ophthalmic | #3 |
| pollen postoperative | #3 |
| conjunctiva conjunctivitis | #3 |
| samples correlate | #3 |
| evaluate tear | #3 |
| vkc 5 eyes | #3 |
| akc biomarkers | #3 |
| improvement squamous metaplasia | #3 |
| 13 eyes 69 | #3 |
| protein conjunctival fibroblasts | #3 |
| 12 akc | #3 |
| conjunctivitis lymphocytes | #3 |
| histamine specimens | #3 |
| pm25 outpatient attendance | #3 |
| higher muc1 eyes | #3 |
| outpatient visits july | #3 |
| signs remission | #3 |
| akc alterations | #3 |
| dibenzoxepins female | #3 |
| oct tmh | #3 |
| mmc authors | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| cytology impression | #3 |
| membrane uncontrollable | #3 |
| fibronectin vkc | #3 |
| diabetic corneal disease | #3 |
| sde controls | #3 |
| periostin comorbidities | #3 |
| dfna eye | #3 |
| immunosuppressive eye | #3 |
| epinastine placebo | #3 |
| techniques tears | #3 |
| eyes vkc | #3 |
| akc eyes | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| measurements schirmer | #3 |
| antibody titers ade | #3 |
| eosinophils corneal | #3 |
| ebv ade | #3 |
| existence par2 | #3 |
| permeability postoperatively | #3 |
| insufficient tear supply | #3 |
| akc rose bengal | #3 |
| severe allergic patients | #3 |
| autumnal pollen | #3 |
| allergic cornea | #3 |
| tryptase increases | #3 |
| tryptase conjunctiva | #3 |
| eye cooling | #3 |
| laser flarecellmetry | #3 |
| akc confocal | #3 |
| patients pilocarpine tablets | #3 |
| corneal epithelial structure | #3 |
| corneal akc | #3 |
| allergic corneal diseases | #3 |
| pretreatment docosahexaenoic acid | #3 |
| 01 bromfenac | #3 |
| vkc long | #3 |
| traumatic swelling | #3 |
| pollen august | #3 |
| mmc excision | #3 |
| eyes akc | #3 |
| conjunctivitis pm25 | #3 |
| patching patient | #3 |
| conjunctivitis negative | #3 |
| cholinergic treatment response | #3 |
| sdedry eye | #3 |
| outpatient visits august | #3 |
| par2 cultured | #3 |
| technique uncontrollable | #3 |
| strip meniscometry testing | #3 |
| ocular surface diabetes | #3 |
| central corneal temperature | #3 |
| 1 month initiation | #3 |
| cases vkc | #3 |
| lacrimal punctal occlusion | #3 |
| nuclei vkc | #3 |
| vkc eyes | #3 |
| ulcer persistent | #3 |
| histamine conjunctival cells | #3 |
| vkc papillae | #3 |
| treatment vernal | #3 |
| superior keratoconjunctiva | #3 |
| solutions prospective | #3 |
| ecp severity | #3 |
| pm25 allergic | #3 |
| keratoconjunctivitis vkc | #3 |
| drop selected | #3 |
| july pm25 | #3 |
| keratoconjunctivitis leupeptins | #3 |
| rtpcr par2 | #3 |
| study cutometer | #3 |
| 5 eyes akc | #3 |
| erosions refractory | #3 |
| cases vernal | #3 |
| cultured tryptase | #3 |
| laser cellflaremetry | #3 |
| cells brush cytology | #3 |
| epithelium adverse | #3 |
| histamine cedar pollen | #3 |
| periostin topical | #3 |
| formation vkc | #3 |
| cornea atopic | #3 |
| dfna eye dfna | #3 |
| 005 mmc | #3 |
| antiallergic eye drop | #3 |
| conjunctiva allergic | #3 |
| thermography evaluate | #3 |
| 22 eyes 100 | #3 |
| healing dramatic healing | #3 |
| cell metry | #3 |
| tears adolescent | #3 |
| tear periostin biomarker | #3 |
| nbs normal eyes | #3 |
| portable recordable | #3 |
| 21 akc patients | #3 |
| eyes control subjects | #3 |
| macroerosions | #3 |
| treatment oral pilocarpine | #3 |
| corneal ulceration role | #3 |
| adedry eye | #3 |
| child conjunctiva | #3 |
| vkc cell | #3 |
| tear periostin patients | #3 |
| akc persistent | #3 |
| icecold eye mask | #3 |
| allergic conjunctivitis aged | #3 |
| ophthalmic solution placebo | #3 |
| conjunctival corneal | #3 |
| eyes allergic | #3 |
| relevant factor exacerbation | #3 |
| periostin akc | #3 |
| giant papilla | #3 |
| 111 177 | #3 |
| akc periostin | #3 |
| phenomena tacrolimus | #3 |
| vkc sac | #3 |
| severe allergy patients | #3 |
| diclofenac eye drops | #3 |
| nonpreserved artificial tears | #3 |
| healing allergic | #3 |
| inflammation mmc | #3 |
| alterations tear | #3 |
| dry eye eye | #3 |
| tissue remodeling exacerbation | #3 |
| sligkv examined | #3 |
| male ophthalmic | #4 |
| allergies blinding | #4 |
| scores conjunctival | #4 |
| conjunctivitis vkc | #4 |
| conjunctivitis ige | #4 |
| eye sjögrens syndrome | #4 |
| trantas | #4 |
| bromfenac eye drops | #4 |
| muc16 goblet | #4 |
| specimens underwent | #4 |
| p0001 brush | #4 |
| compared vkc | #4 |
| allergic conjunctival | #4 |
| completely severe | #4 |
| epithelial muc | #4 |
| thinoptx lens | #4 |
| membrane patching | #4 |
| recordable slit | #4 |
| excision papillary | #4 |
| erosion shield | #4 |
| muc5ac brush | #4 |
| crth2 peripheral | #4 |
| muc16 muc5ac alterations | #4 |
| akc crth2 | #4 |
| diameter allergen | #4 |
| months papillary | #4 |
| underwent corneal | #4 |
| pgd2dependent migration eosinophils | #4 |
| immunologic receptors akc | #4 |
| greater 3 grade | #4 |
| surface conjunctival | #4 |
| muc5ac alterations | #4 |
| eosinophils receptor crth2 | #4 |
| correlation outpatient | #4 |
| acds ophthalmologists | #4 |
| interleukin2 tears | #4 |
| cornea grading scale | #4 |
| chemokine genes fibroblasts | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| akc immunologic receptors | #4 |
| cytometry mild cases | #4 |
| allergic conjunctival disease | #4 |
| assay pgd2 | #4 |
| metaplasia reduction | #4 |
| metaregression analysis effects | #4 |
| solutions piperidines | #4 |
| histamine h1 antagonist | #4 |
| ded 1 | #4 |
| sac grade | #4 |
| primary sources chemokines | #4 |
| vkc 4 | #4 |
| bromfenac ophthalmic | #4 |
| cases sufficient examination | #4 |
| corneal sensitivity measurement | #4 |
| moisture checker | #4 |
| 2010 allergic | #4 |
| rsv allergic reaction | #4 |
| tears patients | #4 |
| allergic epidemiologic studies | #4 |
| topical 01 tacrolimus | #4 |
| treatment vmr | #4 |
| muc5ac mrna expression | #4 |
| acuity akc | #4 |
| 061 028 degree | #4 |
| tears pathogenesis | #4 |
| pgd2dependent migration | #4 |
| allergic patients elisa | #4 |
| alterations atopic | #4 |
| insignificant epithelial | #4 |
| giemsas staining | #4 |
| noninfectious necrotizing | #4 |
| samples allergic | #4 |
| sterilized asian dust | #4 |
| untreated asian dust | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| grade dry eye | #4 |
| lower tear function | #4 |
| eotaxin1 rantes | #4 |
| july pollen | #4 |
| severe vkc patients | #4 |
| simple resection | #4 |
| akc crth2 expression | #4 |
| acds conventional | #4 |
| interferometry 2 | #4 |
| papillae giant | #4 |
| interferometry grade | #4 |
| eye operation | #4 |
| tnfalpha30ng | #4 |
| aged rose | #4 |
| 4 chemokines stimulation | #4 |
| genes conjunctival | #4 |
| special brush | #4 |
| thinoptx | #4 |
| portable slit | #4 |
| include ocular | #4 |
| atopic dermatitis remission | #4 |
| patients severe vkc | #4 |
| pathogenesis noninfectious | #4 |
| formation conjunctivitis | #4 |
| conventional portable | #4 |
| ocular surface epithelial | #4 |
| dust wheal | #4 |
| performed tears | #4 |
| samples histocytological | #4 |
| patients epithelial disease | #4 |
| oedema papillary | #4 |
| pcr epithelial | #4 |
| controls brush cytology | #4 |
| papillae normal | #4 |
| tacrolimus conclusions | #4 |
| rejection limbal | #4 |
| ophthalmologists evaluated | #4 |
| ulcers atopic | #4 |
| interferometry controls | #4 |
| 10 seconds temperature | #4 |
| interferometry lipids | #4 |
| implantation thinoptx | #4 |
| epithelial cells rsv | #4 |
| asian dust extract | #4 |
| patient eyes fluorescein | #4 |
| vkc messenger reverse | #4 |
| temperature corneal | #4 |
| atopic ocular | #4 |
| ulcers control subjects | #4 |
| drop artificial tears | #4 |
| crth2 akc | #4 |
| 3004 respondents | #4 |
| tomography tear | #4 |
| staining muc16 | #4 |
| thinoptx acrysof | #4 |
| 33 chemokines | #4 |
| tablets tears | #4 |
| conjunctival papillary | #4 |
| sensitization asian dust | #4 |
| conjunctival proliferative | #4 |
| implantation rollable | #4 |
| corneal ulcers eyes | #4 |
| corneal temperature blink | #4 |
| fibroblasts primary sources | #4 |
| highrisk glaucoma patients | #4 |
| fva treatment | #4 |
| exponential equation inclination | #4 |
| eyes epithelial disease | #4 |
| hypersensitivity mucin | #4 |
| 2 4 alterations | #4 |
| proteinchip array elisa | #4 |
| weeks vital | #4 |
| keratoconjunctivitis lacrimal | #4 |
| ari ono2235 | #4 |
| epithelial disease eyes | #4 |
| staining muc | #4 |
| akc pgd2dependent migration | #4 |
| akc sac | #4 |
| sterilized asian | #4 |
| vkc male receptors | #4 |
| epinastine hydrochloride | #4 |
| persistent 6 | #4 |
| muc5ac brush cytology | #4 |
| eye wash solution | #4 |
| severe ocular allergies | #4 |
| keratoconjunctivitis purpose | #4 |
| pgd2 normal volunteers | #4 |
| akc chemotaxis | #4 |
| corneal safety | #4 |
| 34 15 seconds | #4 |
| tear temperature | #4 |
| ophthalmologists eye drops | #4 |
| defensins conjunctivitis | #4 |
| diseases portable | #4 |
| mucins 1 | #4 |
| allergic conjunctival diseases | #4 |
| goblet cell muc5ac | #4 |
| controls interferometry | #4 |
| steroids iop | #4 |
| par2 mrna protein | #4 |
| treatment vmr values | #4 |
| chemotaxis conjunctiva | #4 |
| thermometer 20 | #4 |
| studied corneal | #4 |
| atopic ocular allergies | #4 |
| placebo ophthalmic | #4 |
| disease akc | #4 |
| tear function patients | #4 |
| allergic fibroblasts | #4 |
| patients topical cyclosporine | #4 |
| eyes video | #4 |
| lower tear clearance | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| 020 013 | #4 |
| patient atopic keratoconjunctivitis | #4 |
| 0001 brush | #4 |
| mucin mucins tears | #4 |
| eyes corneal ulcers | #4 |
| corneal sensitivity measurements | #4 |
| muc1 2 | #4 |
| vkc normal controls | #4 |
| cultured conjunctival | #4 |
| blinding purpose | #4 |
| eyes insignificant | #4 |
| eyes ulcers | #4 |
| eyes sac | #4 |
| il4 tears | #4 |
| ulcers mucin | #4 |
| epithelial pge2 production | #4 |
| tryptase dose | #4 |
| bengal sensation | #4 |
| microscope evaluating | #4 |
| controls interferometry grade | #4 |
| lesions regrowth | #4 |
| cytometry mild | #4 |
| defensins greater | #4 |
| dscg day | #4 |
| staining ocular | #4 |
| akc rtpcr | #4 |
| photophobia diagnosis | #4 |
| folliculosis | #4 |
| adolescent betamethasone | #4 |
| eyes thinoptx | #4 |
| surface muc5ac | #4 |
| level conjunctiva | #4 |
| deqs scores | #4 |
| greater concentrations tears | #4 |
| p0001 impression | #4 |
| atopic vernal | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| rsv conjunctival epithelium | #4 |
| infected conjunctival | #4 |
| hydrochloride ophthalmic | #4 |
| rsv conjunctiva | #4 |
| epithelial muc16 | #4 |
| eosinophil toxic activity | #4 |
| inflammation akc | #4 |
| cells lnfs | #4 |
| ige conjunctival | #4 |
| conjunctiva differences | #4 |
| sensation tears | #4 |
| conjunctivitis methods | #4 |
| cytology goblet | #4 |
| corneal temperature eye | #4 |
| stimulation chemokine expression | #4 |
| akc healthy individuals | #4 |
| conjunctivitis levels | #4 |
| individuals pgd2 | #4 |
| thermography anterior | #4 |
| akc healthy | #4 |
| cell muc5ac | #4 |
| vmr 3 months | #4 |
| healthy individuals rtpcr | #4 |
| epithelial disease patients | #4 |
| ocular allergic disease | #4 |
| steroids fluorometholone | #4 |
| insignificant epithelial disease | #4 |
| akcaffected patients | #4 |
| clinical conjunctival | #4 |
| allergic conjunctivitis rsv | #4 |
| wilcoxon signed test | #4 |
| mucins tears mucin | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| thinoptx intraocular | #4 |
| levocabastine h1 | #4 |
| corneal ulcers muc5ac | #4 |
| allergic cytological | #4 |
| topical oral steroids | #4 |
| tears 10 patients | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| samples immunocytochemical | #4 |
| subjects muc5ac | #4 |
| limbal grafts | #4 |
| levocabastine ophthalmic | #4 |
| sio2 20 | #4 |
| eyes akc patients | #4 |
| sac control eyes | #4 |
| tear function test | #4 |
| fungi epidemiologic studies | #4 |
| rose bengal scores | #4 |
| 18 akc patients | #4 |
| conjunctiva density | #4 |
| fibroblasts eosinophil adherence | #5 |
| solutions pollen | #5 |
| signs akc | #5 |
| cornea cytodiagnosis | #5 |
| meniscus punctal | #5 |
| ophthalmic test | #5 |
| postsurgical inflammation | #5 |
| stainings tear | #5 |
| crth2 prostaglandin receptors | #5 |
| hne ihc | #5 |
| 310±165 years | #5 |
| ulcer dermatitis | #5 |
| adolescent conjunctivitis | #5 |
| case corneal ulcer | #5 |
| topical cyclosporine therapy | #5 |
| solution olopatadine | #5 |
| pretreatment dha | #5 |
| upper palpebral | #5 |
| disease conjunctivitis | #5 |
| thiazolidines administration | #5 |
| vcam1 fibroblasts | #5 |
| local tear | #5 |
| array chemotaxis | #5 |
| cells vkc | #5 |
| dryeye symptoms | #5 |
| akc disease | #5 |
| scores expressibility | #5 |
| age 9 ± | #5 |
| 329±57 years | #5 |
| eye warmer treatment | #5 |
| measurements strip | #5 |
| fibroblasts fibroblast damage | #5 |
| visits august | #5 |
| conjunctival confocal microscopy | #5 |
| conjunctivitis pollen | #5 |
| oct lower | #5 |
| 15 minutes dose | #5 |
| il4 histamine | #5 |
| allergic drug therapy | #5 |
| intraoperative mitomycin excision | #5 |
| ocular allergic | #5 |
| cases tests | #5 |
| asthenopia dry | #5 |
| eosinophils activated fibroblasts | #5 |
| dryeye symptoms treatment | #5 |
| tnfα costimulation | #5 |
| females akc | #5 |
| 7 conjunctival | #5 |
| corneal involvement | #5 |
| conjunctiva dermatitis | #5 |
| vkc atopic | #5 |
| lipid oxidation hel | #5 |
| months amniotic | #5 |
| hel ihc | #5 |
| temperature blink | #5 |
| akc laser | #5 |
| conjunctival lipid | #5 |
| mitomycin excision | #5 |
| regulation allergic cornea | #5 |
| thinoptx iol | #5 |
| staining administration | #5 |
| human conjunctival fibroblasts | #5 |
| younger age effects | #5 |
| ophthalmic suspension | #5 |
| adhered corneal | #5 |
| accompanying allergic | #5 |
| conjunctival inflammatory status | #5 |
| corneal fibroblasts icam1 | #5 |
| stained conjunctival | #5 |
| hel akc | #5 |
| impression cytology samples | #5 |
| ocular anesthesia | #5 |
| vkc iop | #5 |
| month tear | #5 |
| alterations ocular | #5 |
| severe conjunctivitis | #5 |
| 20 akc patients | #5 |
| pgd2 normal | #5 |
| prostaglandin chemotaxis | #5 |
| disposable eyelid | #5 |
| keratoconjunctivitis giant | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| visits july | #5 |
| 5 females akc | #5 |
| stimulated conjunctival | #5 |
| labeling surface akc | #5 |
| ulcers controls | #5 |
| study epinastine | #5 |
| lower atopic | #5 |
| severe stevensjohnson syndrome | #5 |
| inflammation mitomycin | #5 |
| layer mgd | #5 |
| conventional steroid treatment | #5 |
| simple papillary | #5 |
| conjunctivitis prostaglandin | #5 |
| conjunctiva mmc | #5 |
| treatment dryeye symptoms | #5 |
| akc patients study | #5 |
| schirmer1 test groups | #5 |
| controls ebv | #5 |
| eosinophil adherence fibroblasts | #5 |
| eosinophils immunologic receptors | #5 |
| lesion corneal | #5 |
| diseases required | #5 |
| allergic conjunctivitis patients | #5 |
| akc normal subjects | #5 |
| injection conjunctival | #5 |
| 376±56 years | #5 |
| ihc conjunctival inflammation | #5 |
| alpha allergic | #5 |
| treatment tacrolimus ointment | #5 |
| samples akc | #5 |
| cornea explain | #5 |
| 005 schirmer1 | #5 |
| warmer applied | #5 |
| mcfg eye | #5 |
| bromobenzenes cornea | #5 |
| conjunctival allergen | #5 |
| eye warmer | #5 |
| tears received | #5 |
| 20 sio2 | #5 |
| akc acinar | #5 |
| eye circulating | #5 |
| damage impression | #5 |
| hel cytokines | #5 |
| disposable eyelidwarming device | #5 |
| staining muc5ac | #5 |
| 0001 strip | #5 |
| anterior fluorometry | #5 |
| damaged eosinophil | #5 |
| schiff immunohistochemical | #5 |
| status confocal | #5 |
| supernatants conjunctival | #5 |
| 01 mcfg | #5 |
| keratoconjunctivitis objective | #5 |
| 3 cases followup | #5 |
| treatment epinastine | #5 |
| warmer improved | #5 |
| worse akc | #5 |
| severity akc | #5 |
| allergic female | #5 |
| crth2 eosinophils | #5 |
| pm25 outpatient | #5 |
| eosinophil adhesion fibroblasts | #5 |
| akc hel | #5 |
| controls inflammatory cells | #5 |
| accompanied varying | #5 |
| wilcoxonmatched pair test | #5 |
| impression brush | #5 |
| cytokinestimulation | #5 |
| inflammatory cells hel | #5 |
| akc ecp | #5 |
| situ nickend regulation | #5 |
| endophthalmitis eosinophils | #5 |
| treatment shield | #5 |
| scans akc | #5 |
| equipment dry | #5 |
| punctal occlusion oct | #5 |
| allergic cyclosporine | #5 |
| allergic keratopathy | #5 |
| histamine superficial | #5 |
| ocular surface disorder | #5 |
| trantas dots | #5 |
| 17 mgd patients | #5 |
| anterior scleritis patients | #5 |
| bengal suture | #5 |
| antifungal mcfg | #5 |
| diclofenac eye | #5 |
| tears acinar | #6 |
| agents interferometry | #6 |
| july correlation | #6 |
| female fluorometholone | #6 |
| ade sde | #6 |
| noninvasive suction device | #6 |
| conjunctival confocal | #6 |
| akc refractory | #6 |
| eosinophils crth2 | #6 |
| dfna | #6 |
| 20 pbs | #6 |
| hyperemia imidazoles | #6 |
| samples underwent | #6 |
| antiallergic eye | #6 |
| dressings female | #6 |
| symptoms vkc | #6 |
| topical cys treatment | #6 |
| scores goblet | #6 |
| levels air pollutants | #6 |
| ecp markers | #6 |
| ocular fatigue | #6 |
| specimens akc | #6 |
| intolerable irritation | #6 |
| corneal temperature | #6 |
| sac vkc | #6 |
| allergens cedrus | #6 |
| tranilast inhibition | #6 |
| strip meniscometry scores | #6 |
| functions topical | #6 |
| eye evaluated | #6 |
| tears xerophthalmia | #6 |
| tryptase proliferation | #6 |
| tacrolimus chronic | #6 |
| elevation refractory | #6 |
| conjunctival diseases | #6 |
| oxidation hel | #6 |
| akc vernal keratoconjunctivitis | #6 |
| challenge cac | #6 |
| tear eosinophil | #6 |
| betamethasone oral | #6 |
| corneal damage | #6 |
| tbut vital | #6 |
| treatment postoperative inflammation | #6 |
| allergic conjunctivitis cac | #6 |
| tear ecp | #6 |
| dermatitis scored | #6 |
| patients seldi | #6 |
| topical cys | #6 |
| allergic diathesis | #6 |
| concomitant eye | #6 |
| pcr muc5ac | #6 |
| elasticity cutometer | #6 |
| severe vkc | #6 |
| tear stability values | #6 |
| findings dry eye | #6 |
| rate tbut | #6 |
| il4 il2r | #6 |
| density conjunctival | #6 |
| 4 9 genes | #6 |
| severe vernal | #6 |
| cys ocular | #6 |
| coated elf | #6 |
| levocabastine effective | #6 |
| rtpcr epithelial cells | #6 |
| remodeling vkc | #6 |
| sde ade | #6 |
| atopic eyelids | #6 |
| dust asian | #6 |
| cyclosporine 01 | #6 |
| syndrome tablets | #6 |
| evaporation vital | #6 |
| chloride eye | #6 |
| conjunctival brush cytology | #6 |
| extract sterilized | #6 |
| 4 muc | #6 |
| solution commercial | #6 |
| rose bengal dyes | #6 |
| inflammatory cell densities | #6 |
| itching conjunctival | #6 |
| upper tarsal conjunctiva | #6 |
| pathogenesis ocular | #6 |
| conjunctivitis sac | #6 |
| hyperemia swelling | #6 |
| patients visante | #6 |
| testing tear | #6 |
| grading tear | #6 |
| severe stevens | #6 |
| papillae mucous | #6 |
| instability conjunctival | #6 |
| diseases periostin | #6 |
| edema severity | #6 |
| defect ped | #6 |
| examinations tear | #6 |
| ocular surface findings | #6 |
| treatment tacrolimus | #6 |
| defect penetrating | #6 |
| induced tear | #6 |
| differences tear | #6 |
| twicedaily instillation | #6 |
| signs scored | #6 |
| schirmer1 test values | #6 |
| fva landolt | #6 |
| controlling eyelid | #6 |
| fluorometholone follow | #6 |
| corneal fibroblasts pathogenesis | #6 |
| eyes atopic | #6 |
| cgvhd improvements | #6 |
| bengal vital stainings | #6 |
| regulation benzamidines | #6 |
| topical levocabastine | #6 |
| obstructive mgd patients | #6 |
| tear meniscus patients | #6 |
| fibroblasts conjunctival | #6 |
| ointment blood | #6 |
| severe ocular inflammation | #6 |
| eosinophil recruiting chemokines | #6 |
| age 325 years | #7 |
| ocular inflammatory disorder | #7 |
| nerves tear | #7 |
| pge2 cox2 levels | #7 |
| administration fluorescein | #7 |
| ulceration healthy | #7 |
| solution bf | #7 |
| revealed eosinophils | #7 |
| evaluation eyelid | #7 |
| examination tear | #7 |
| inhibitor ono2235 | #7 |
| sensitization asian | #7 |
| allergic dna | #7 |
| tears th2 | #7 |
| 4 tear | #7 |
| neutrophils corneal | #7 |
| conjunctival brush | #7 |
| cytology differ | #7 |
| tears alpha | #7 |
| adult blepharitis | #7 |
| mucins tears | #7 |
| patients comfort level | #7 |
| papillae formation | #7 |
| incidence meibomian | #7 |
| hyperemia adverse | #7 |
| conjunctival inflammatory | #7 |
| western blotting nfκb | #7 |
| ulcer corneal | #7 |
| silicone plugs | #7 |
| cases preventing | #7 |
| improvements symptom scores | #7 |
| conclusion mmc | #7 |
| eyelid surface | #7 |
| steroidal benzophenones | #7 |
| conjunctiva brush | #7 |
| suspension 01 | #7 |
| mucins periodic | #7 |
| severe persistent cases | #7 |
| conjunctivitis dry | #7 |
| surgery cooling | #7 |
| tear supply | #7 |
| tacrolimus topical steroids | #7 |
| tacrolimustreated eyes | #7 |
| eczema frequently | #7 |
| chemotaxis eosinophils | #7 |
| vkc gpc | #7 |
| rose bengal fluorescein | #7 |
| status atopic | #7 |
| injection oedema | #7 |
| development allergic conjunctivitis | #7 |
| necrotizing anterior | #7 |
| tmh measurements | #7 |
| allergic eyelid | #7 |
| alpha tears | #7 |
| meniscometry testing | #7 |
| thought pathogenesis | #7 |
| corneal lesion | #7 |
| pgd2 dependent | #7 |
| gpc vkc | #7 |
| 0001 impression | #7 |
| conjunctivitis risk | #7 |
| hrtii rcm | #7 |
| sources chemokines | #7 |
| attendance allergic | #7 |
| collected brush | #7 |
| normal blinking | #7 |
| mmc 005 | #7 |
| eyes ophthalmologists | #7 |
| accommodating intraocular lens | #7 |
| key prostaglandin | #7 |
| increases proliferative | #7 |
| procedures radioimmunoassay | #7 |
| 10 clinical signs | #7 |
| mmc observed | #7 |
| sensation symptom | #7 |
| superiority placebo | #7 |
| concentrations conjunctival | #7 |
| nonparametric tears | #7 |
| conjunctival complications | #7 |
| ulcers revealed | #7 |
| amniotic membrane patching | #7 |
| prostaglandin atopic | #7 |
| pathogenesis subsequent | #7 |
| crth2 normal | #7 |
| conjunctival findings | #8 |
| patients corneal | #8 |
| 006 degree | #8 |
| tnfalpha eosinophils | #8 |
| oedema scores | #8 |
| superficial cells groups | #8 |
| graticule scale | #8 |
| corneal scores | #8 |
| teros values | #8 |
| par2 mast cells | #8 |
| noninfectious corneal | #8 |
| controls seldi | #8 |
| techniques keratoconjunctivitis | #8 |
| brush cytology | #8 |
| infrared radiation thermometry | #8 |
| patients vkc | #8 |
| occlusion lacrimal | #8 |
| mitomycin post | #8 |
| correlation vital | #8 |
| chemotaxis pgd2 | #8 |
| scores teros | #8 |
| ihc hel | #8 |
| underwent tear | #8 |
| corneal epithelial lesions | #8 |
| transient burning sensation | #8 |
| blinking desiccation | #8 |
| meniscometry scores | #8 |
| staining hel | #8 |
| pathogenesis test | #8 |
| itching hyperemia | #8 |
| age 170 ± | #8 |
| limbalbased conjunctival flap | #8 |
| fva measurements | #8 |
| keratocytes cytokines | #8 |
| akc patients controls | #8 |
| diameter acinar | #8 |
| alterations cornea | #8 |
| induced intraocular | #8 |
| stained hel | #8 |
| meniscometry tear | #8 |
| radiation thermography | #8 |
| microscopy conjunctival | #8 |
| palpebral bulbar | #8 |
| blink patients | #8 |
| expressions thought | #8 |
| flare counts | #8 |
| conjunctival sensation | #8 |
| ccl5 conjunctiva | #8 |
| asia cats | #8 |
| hoc analysis study | #8 |
| corneal ulcer | #8 |
| values slit | #8 |
| classified allergic | #8 |
| allergic dibenzazepines | #8 |
| trabeculectomy amniotic | #8 |
| il4 enzyme | #8 |
| teros | #8 |
| surface teros | #8 |
| alterations allergic | #8 |
| pollen odds | #8 |
| eye redness | #8 |
| betamethasone calcineurin | #8 |
| akc subjects | #8 |
| 4 chemokines | #8 |
| stainings schirmer | #8 |
| sac akc | #8 |
| definite dry eye | #8 |
| corneal fibroblasts tnfalpha | #8 |
| conjunctivitis eyes | #8 |
| fluorescein rose bengal | #8 |
| rollable intraocular | #8 |
| ulcers detected | #8 |
| blinking body | #8 |
| controls brush | #8 |
| patients tacrolimus treatment | #9 |
| histocytological study | #9 |
| tacrolimus treating | #9 |
| prevalence weather | #9 |
| pathogen allergic | #9 |
| wash solution | #9 |
| tnfalpha fibroblasts | #9 |
| differ allergic | #9 |
| cobblestone papillae | #9 |
| acid goblet | #9 |
| design eyelid | #9 |
| blood level tacrolimus | #9 |
| symptoms allergic conjunctivitis | #9 |
| crth2 expression eosinophils | #9 |
| stress staining | #9 |
| measurements vital | #9 |
| eye grade | #9 |
| pretreatment docosahexaenoic | #9 |
| prospective study tacrolimus | #9 |
| prevalence vkc | #9 |
| injection edema | #9 |
| 0001 schirmer | #9 |
| supply superior | #9 |
| tear level | #9 |
| untreated asian | #9 |
| diseases conjunctivitis | #9 |
| sio2 pbs | #9 |
| pollution conjunctivitis | #9 |
| received preserved | #9 |
| fluorescein rose | #9 |
| sensitivity conjunctival | #9 |
| sensitivity confocal | #9 |
| specular microscopic evaluation | #9 |
| sufficient examination | #9 |
| eye normal subjects | #9 |
| diagnosis conjunctivitis | #9 |
| cys eye | #9 |
| hyperemia iop | #9 |
| concentration tears | #9 |
| shield ulcers | #9 |
| ono2235 | #9 |
| excision intraoperative | #9 |
| reductase cataract | #9 |
| smart eye | #9 |
| observed obstructive | #9 |
| foreign body sensation | #9 |
| subjective ocular | #9 |
| conjunctivitis cases | #9 |
| inflammation steroidal | #9 |
| cases conjunctivitis | #9 |
| superior limbic | #9 |
| severity corneal | #9 |
| fatigue dry | #9 |
| tacrolimus 95 | #9 |
| tears thermography | #9 |
| vital staining scores | #9 |
| elisa tears | #9 |
| genes cxc | #9 |
| glaucoma younger age | #9 |
| mmc recurrence | #9 |
| implantation 1cu | #9 |
| hel 4 | #9 |
| operatedon eye | #9 |
| vital stainings | #9 |
| pilocarpine tablets | #9 |
| clinical ocular findings | #9 |
| level pollutants | #9 |
| conjunctival fibroblast | #9 |
| conjunctival edema | #10 |
| produced conjunctival | #10 |
| scale tear | #10 |
| iop hyperemia | #10 |
| status conjunctival | #10 |
| chemokines cxc chemokines | #10 |
| allergic conjunctivitis spring | #10 |
| vmr values | #10 |
| compared eyes | #10 |
| lower tmh | #10 |
| assessed conjunctival | #10 |
| punctal occlusion | #10 |
| complain | #10 |
| diagnosis dry eye | #10 |
| functions dry | #10 |
| cytometry il4 | #10 |
| staining oral | #10 |
| crth2 chemotaxis | #10 |
| measurement strip | #10 |
| icam1 tnfalpha | #10 |
| resection regrowth | #10 |
| underwent slit | #10 |
| patients ulcers | #10 |
| conjunctivitis japan | #10 |
| eye surface | #10 |
| conjunctivitis histamine | #10 |
| incubated il4 | #10 |
| nonallergic conjunctivitis | #10 |
| substance tears | #10 |
| staining brush | #10 |
| aged conjunctivitis | #10 |
| laminin actins | #10 |
| leupeptin benzamidine | #10 |
| visante optical | #10 |
| par2 mast | #10 |
| ophthalmic adolescent | #10 |
| bengal stainings | #10 |
| tear cytology | #10 |
| proliferation conjunctival | #10 |
| allergic ocular | #10 |
| eye infrared | #10 |
| improvement tear | #10 |
| measuring tear | #10 |
| muc5ac muc16 | #10 |
| eye clinically | #10 |
| evaluation atopic | #10 |
| tears 10 | #10 |
| humans conjunctival | #10 |
| drugs conjunctival | #10 |
| cornea eosinophils | #10 |
| conjunctivitis spring | #10 |
| insufficient local | #10 |
| allergic bronchitis | #10 |
| central graft | #10 |
| treatment vkc | #10 |
| sensation ocular | #10 |
| total tear ige | #10 |
| conjunctivitis atopic | #10 |
| muc16 muc5ac | #10 |
| levels tears | #10 |
| shield ulcer | #10 |
| humans mucin | #10 |
| subbasal stromal | #10 |
| meibomian gland obstruction | #10 |
| lacrimal puncta | #10 |
| topical cyclosporine patients | #10 |
| layer alterations | #10 |
| prevalence dry eye | #11 |
| preserved artificial | #11 |
| methods conjunctival | #11 |
| vmr fva | #11 |
| schirmer1 test | #11 |
| hel hne | #11 |
| tears conjunctival | #11 |
| sensation tear | #11 |
| cooling operation | #11 |
| matched dry | #11 |
| cytometry oligonucleotide | #11 |
| sensation staining | #11 |
| eosinophils prostaglandin | #11 |
| palpebral bulbar conjunctiva | #11 |
| count conjunctivitis | #11 |
| interleukin4 male | #11 |
| drop artificial | #11 |
| diagnosis allergic | #11 |
| landolt visual | #11 |
| ophthalmic solution | #11 |
| antivcaigg | #11 |
| genes corneal | #11 |
| vernal | #11 |
| lamp microscope | #11 |
| higher muc1 | #11 |
| vkc normal | #11 |
| levocabastine hydrochloride | #11 |
| therapy conjunctivitis | #11 |
| surgery 13 eyes | #11 |
| elisa il4 | #11 |
| disease edition | #11 |
| vcam1 tnfalpha | #11 |
| association outpatient | #11 |
| common conjunctival | #11 |
| 1 month reduction | #11 |
| elasticity treatment | #11 |
| anesthesia strabismus | #11 |
| weeks papillary | #11 |
| elicited statistically | #11 |
| patient atopic | #11 |
| amniotic membrane patch | #11 |
| vkc | #11 |
| initiation tacrolimus | #11 |
| coherence dry | #11 |
| test tear | #11 |
| vkc adolescent | #11 |
| purpose metaplasia | #11 |
| function ocular | #11 |
| keratitis observed | #11 |
| fibroblasts pathogenesis | #11 |
| smart eye camera | #11 |
| radiography tears | #12 |
| keratoplasty glaucoma | #12 |
| tears conjunctivitis | #12 |
| 001 specimens | #12 |
| conventional slit | #12 |
| leupeptins mast | #12 |
| fva visual | #12 |
| iop younger | #12 |
| keratoconjunctivitis patients | #12 |
| conjunctival injection | #12 |
| specimens eyes | #12 |
| acids chemokine | #12 |
| pemirolast potassium | #12 |
| fluorescein scores | #12 |
| 1821 subjects | #12 |
| extracts pollens | #12 |
| controls antibody titers | #12 |
| microscopy efficient | #12 |
| iop glucocorticoids humans | #12 |
| lacrimal punctal | #12 |
| fva vmr | #12 |
| selected severity | #12 |
| mmhg elevation | #12 |
| receptor crth2 | #12 |
| dermatitis tacrolimus | #12 |
| findings conjunctival | #12 |
| coated lactoferrin | #12 |
| cornea density | #12 |
| appearance atopic | #12 |
| biomarker allergic | #12 |
| projects tears | #12 |
| surface diabetic | #12 |
| 002 ophthalmic | #12 |
| drugs pge2 | #12 |
| levocabastine patients | #12 |
| highspeed highresolution | #12 |
| ulcers squamous | #12 |
| immunologic rejection | #12 |
| expression 8 genes | #12 |
| 1cu accommodating | #12 |
| supratarsal injection | #12 |
| 1cu iol | #12 |
| patients sac | #12 |
| corneal aesthesiometry | #12 |
| severe binocular | #12 |
| density acinar | #12 |
| damage height | #12 |
| ccl11 conjunctiva | #12 |
| eye diagnosed | #12 |
| mgd controls | #12 |
| density muc5ac | #12 |
| corneal shield | #12 |
| coherence viscosupplements | #13 |
| syndrome reactivation | #13 |
| tear hel | #13 |
| inflammation tear | #13 |
| applied operation | #13 |
| scraped samples | #13 |
| keratocytes incubated | #13 |
| tear functions | #13 |
| 5ac ophthalmic | #13 |
| remodeling relevant | #13 |
| upper tarsal | #13 |
| treatment allergic conjunctivitis | #13 |
| temperature cataract | #13 |
| protein conjunctival | #13 |
| cell flare | #13 |
| thirty eyes | #13 |
| bengal fluorescein | #13 |
| aged disposable | #13 |
| conjunctival oedema | #13 |
| ulcers corneal | #13 |
| schirmers test values | #13 |
| months healed | #13 |
| suspensions tacrolimus | #13 |
| anterior segment photography | #13 |
| conclusions ocular | #13 |
| called giant | #13 |
| outcomes 01 | #13 |
| glaucoma younger | #13 |
| topical cyclosporine treatment | #13 |
| dry eye examination | #13 |
| time fluorescein | #13 |
| improvement vital | #13 |
| stability vital | #13 |
| symptoms conjunctival | #13 |
| corneal complications | #13 |
| vmr measurements | #13 |
| papillary samples | #13 |
| chemokines stimulation | #13 |
| japan keratoconjunctivitis | #13 |
| epithelial disease | #13 |
| objective signs | #13 |
| week corneal | #13 |
| sd105 | #13 |
| interferometry tear | #13 |
| glaucoma keratoplasty | #13 |
| blood levels tacrolimus | #13 |
| specimens levels | #13 |
| fluorometholone fml | #13 |
| compared postsurgical | #13 |
| clinically allergic | #14 |
| conjunctival impression | #14 |
| clinical corneal | #14 |
| visits allergic | #14 |
| conjunctival allergen challenge | #14 |
| proliferative lesion | #14 |
| conjunctival muc5ac | #14 |
| functions corneal | #14 |
| cornea endophthalmitis | #14 |
| solutions retrospective | #14 |
| test rose | #14 |
| conjunctivitis vernal | #14 |
| dry eye controls | #14 |
| density tear | #14 |
| conjunctivitis background | #14 |
| mcfg treatment | #14 |
| factors conjunctivitis | #14 |
| bf 01 | #14 |
| fibroblast damage | #14 |
| higher allergic | #14 |
| eyes 002 | #14 |
| occlusion dry | #14 |
| schirmer1 | #14 |
| 14 flare | #14 |
| fungi adolescent | #14 |
| epithelial muc5ac | #14 |
| blinking patients | #14 |
| pilocarpine effective | #14 |
| flare count | #14 |
| benzamidines blotting | #14 |
| fluorometholone humans | #14 |
| secrete mediators | #14 |
| vehicle eye | #14 |
| radioimmunoassay tears | #14 |
| adherence fibroblasts | #15 |
| corneal recurrence | #15 |
| occlusion rose | #15 |
| bilateral conjunctivitis | #15 |
| day bf | #15 |
| ocular surface mucins | #15 |
| ulcer echinocandins | #15 |
| analysis par2 | #15 |
| improvement corneal | #15 |
| tranilast anti | #15 |
| mmc female follow | #15 |
| bromobenzenes child | #15 |
| complications height | #15 |
| cytology brush | #15 |
| effects benzalkonium | #15 |
| improvement subjective symptoms | #15 |
| investigated corneal | #15 |
| agents blepharitis | #15 |
| diseases 2020 | #15 |
| mucous discharge | #15 |
| examined existence | #15 |
| topical 01 | #15 |
| receptor pgd2 | #15 |
| olopatadine 01 | #15 |
| eye drop treatment | #15 |
| surface vital | #15 |
| patients vernal | #15 |
| steroidal cornea | #15 |
| superior conjunctiva | #15 |
| monitoring tear | #15 |
| rtpcr cytometry | #15 |
| ocular itching | #15 |
| complications mmc | #15 |
| basal tear secretion | #15 |
| ophthalmology tokyo | #15 |
| firstline drug | #15 |
| giant papillary | #15 |
| ige ecp | #15 |
| evaluation conjunctival | #15 |
| expression realtime pcr | #15 |
| occlusion oct | #15 |
| tmh values | #15 |
| irritation scores | #15 |
| ocular acrylic | #15 |
| vkc methods | #15 |
| blepharitis conjunctivitis | #15 |
| damaged fibroblasts | #15 |
| correlation tear | #15 |
| safety 01 | #16 |
| temperature conjunctiva | #16 |
| odds ratio remission | #16 |
| total clinical scores | #16 |
| measurements tear | #16 |
| controls papillary | #16 |
| female goblet | #16 |
| dust allergic | #16 |
| objective ocular | #16 |
| ige correlation | #16 |
| treatment eyelid | #16 |
| segment photography | #16 |
| lacrimation | #16 |
| 2 conjunctival | #16 |
| assessment conjunctival | #16 |
| alpha ortho | #16 |
| eosinophils receptor | #16 |
| hours visit | #16 |
| fungi odds | #16 |
| reduction goblet | #16 |
| patients vernal keratoconjunctivitis | #16 |
| ari administration | #16 |
| ulcers positive | #16 |
| ocular allergic inflammation | #17 |
| inhibitor ari | #17 |
| increased goblet cells | #17 |
| 20 normal patients | #17 |
| agents cedrus | #17 |
| staining muc1 | #17 |
| signs ded | #17 |
| fibroblasts mcp1 | #17 |
| 13 females age | #17 |
| evaluation inflammatory | #17 |
| inflammation blotting | #17 |
| conjunctival samples | #17 |
| sclera trabeculectomy | #17 |
| warmer treatment | #17 |
| strip meniscometry | #17 |
| expression eotaxin1 | #17 |
| betamethasone induced | #17 |
| meniscometry | #17 |
| analyzed 005 | #17 |
| clearance corneal | #17 |
| drops eyes | #17 |
| eyes schirmer | #17 |
| corneal sensation | #17 |
| age dry | #17 |
| initiation objective | #17 |
| muc16 mrna | #17 |
| wear soft | #17 |
| fibroblasts damaged | #17 |
| ceramide gel | #17 |
| decrease ocular | #18 |
| tear function | #18 |
| groups spt | #18 |
| complete staining | #18 |
| ocular surface status | #18 |
| differentiation inflammatory cells | #18 |
| cytology corneal | #18 |
| obstructive dysfunction | #18 |
| pollen fungi | #18 |
| tnfα inflammatory response | #18 |
| dibenzazepines dibenzoxepins | #18 |
| cd45 inflammatory | #18 |
| conclusion ocular | #18 |
| concentrations corneal | #18 |
| fibroblasts giant | #18 |
| noncl wearers | #18 |
| types dry eye | #18 |
| lower eyes | #18 |
| trabeculectomy glaucoma | #18 |
| rantes response | #18 |
| intraoperative 002 | #18 |
| studies rose | #18 |
| test tears | #18 |
| cytology decrease | #18 |
| ulcers compared | #18 |
| ulceration subjects | #18 |
| bengal sjogren | #18 |
| induce corneal | #18 |
| technique glaucoma | #18 |
| evaluation tear | #18 |
| correlation clinical signs | #18 |
| inflammation lenses | #18 |
| male ophthalmic solutions | #18 |
| associations level | #18 |
| 30 ige | #18 |
| tear evaporation rate | #18 |
| higher tears | #18 |
| mitomycin ophthalmologic | #19 |
| periostin biomarker | #19 |
| effective tacrolimus | #19 |
| dha pretreatment | #19 |
| measurements visante | #19 |
| operation applied | #19 |
| outpatient attendance | #19 |
| staining scores | #19 |
| aged cautery | #19 |
| seldi proteinchip | #19 |
| temperature artificial | #19 |
| ige tear | #19 |
| evaluated infrared | #19 |
| 1151 years | #19 |
| microscopy scans | #19 |
| steroid female | #19 |
| limbal allograft | #19 |
| sodium 01 | #19 |
| aged ophthalmic | #19 |
| prospective study eyes | #19 |
| 3 severe | #19 |
| seldi analysis | #19 |
| human conjunctival | #19 |
| beta1 il1beta | #19 |
| early efficacy | #19 |
| total signs | #19 |
| vernal keratoconjunctivitis | #19 |
| sma performed | #19 |
| subjects underwent | #19 |
| eosinophils adhered | #19 |
| inflammatory cells patients | #19 |
| conjunctivitis topical | #19 |
| summarized based | #20 |
| evaluate noninferiority | #20 |
| common ocular disorders | #20 |
| treated 01 | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| plaques graded | #20 |
| 022 pg | #20 |
| conjunctivitis primary | #20 |
| persistent epithelial defect | #20 |
| decreased conjunctival | #20 |
| lower dry | #20 |
| pollen association | #20 |
| echinocandins eye | #20 |
| conclusion tacrolimus | #20 |
| proteins tears | #20 |
| patients strip | #20 |
| symptoms allergic | #20 |
| tears corneal | #20 |
| surface findings | #20 |
| improvements ocular | #20 |
| mucin alterations | #20 |
| ulcers cell | #20 |
| explain pathogenesis | #20 |
| bilateral agerelated cataract | #20 |
| corneal impression | #20 |
| allergic female humans | #20 |
| conjunctivitis caused | #20 |
| cytology upper | #20 |
| height tmh | #20 |
| xerophthalmia adolescent | #20 |
| radiation thermometer | #21 |
| conclusions topical | #21 |
| methane nonmethane hydrocarbons | #21 |
| crth2 expressed | #21 |
| adhesion fibroblast | #21 |
| levels hel | #21 |
| eye smaller | #21 |
| symptoms include | #21 |
| fluorescence postoperative | #21 |
| reaction tears | #21 |
| reduction topical | #21 |
| induced topical | #21 |
| surface mucin | #21 |
| cornea clinical | #21 |
| patients cedar | #21 |
| film lipid | #21 |
| conjunctiva role | #21 |
| patients concomitant treatment | #21 |
| eosinophils flow cytometry | #21 |
| microscopy patients | #21 |
| eye control | #21 |
| acuity assessment | #21 |
| keratoconjunctivitis atopic | #21 |
| peripheral blood eosinophils | #21 |
| preventing corneal | #21 |
| lipid oxidative | #21 |
| ige groups | #21 |
| ocular symptoms signs | #21 |
| tears blood | #21 |
| cultured conjunctiva | #21 |
| fibroblasts anti | #22 |
| eyes nerve | #22 |
| therapies allergic | #22 |
| types ocular | #22 |
| haze photorefractive | #22 |
| fluorescein staining | #22 |
| 01 tacrolimus | #22 |
| serum periostin patients | #22 |
| 005 topical | #22 |
| correlation humidity | #22 |
| flare anterior | #22 |
| mgd adult | #22 |
| accommodation amplitude | #22 |
| muc5ac patients | #22 |
| epithelial lipid | #22 |
| negative lower | #22 |
| lamp examinations | #23 |
| 215 ± | #23 |
| solution corneal | #23 |
| 01 severe | #23 |
| solution compared | #23 |
| corneal fluorescein | #23 |
| layer interferometry | #23 |
| score deqs | #23 |
| prospectively surgery | #23 |
| 5 females | #23 |
| il4 tnf | #23 |
| tear dynamics | #23 |
| cooling applied | #23 |
| function mucin | #23 |
| subjects squamous | #23 |
| hrt confocal | #23 |
| diseases diclofenac | #23 |
| pge2 supernatants | #23 |
| disease atopic | #23 |
| tests adenovirus | #23 |
| palpebral conjunctiva | #23 |
| blood concentration tacrolimus | #23 |
| preschool conjunctivitis | #23 |
| patients topical steroids | #23 |
| labeling tears | #23 |
| conjunctiva diabetes | #24 |
| control tear | #24 |
| surface tear | #24 |
| vital staining | #24 |
| dermatitis improved | #24 |
| patients tacrolimus ointment | #24 |
| 27yearold male patient | #24 |
| warming device | #24 |
| cell meter | #24 |
| bengal tears | #24 |
| tarsal conjunctiva | #24 |
| ocular allergies | #24 |
| diseases web | #24 |
| vkc patients | #24 |
| formation allergic | #24 |
| edema drug | #24 |
| signs serum | #24 |
| local allergic reaction | #24 |
| layer tear | #24 |
| histamine development | #24 |
| interleukin4 oligonucleotide | #24 |
| fungal corneal | #24 |
| samples conjunctival | #24 |
| tokyo dental | #24 |
| bengal scores | #25 |
| corneal plaques | #25 |
| patients atopic diseases | #25 |
| confocal prospective | #25 |
| vkc compared | #25 |
| slitlamp examinations | #25 |
| staining goblet | #25 |
| schedule eosinophil | #25 |
| protein rtpcr | #25 |
| atopic eosinophils humans | #25 |
| vcam1 activated | #25 |
| superficial cells | #25 |
| level tears | #25 |
| rsv rtpcr | #25 |
| density squamous | #25 |
| dynamics tear | #25 |
| rtpcr rsv | #25 |
| eyes epithelial | #25 |
| 0001 dry | #25 |
| antigen conjunctiva | #25 |
| steroid eye | #25 |
| human α defensin | #26 |
| actins collagen | #26 |
| acinar unit | #26 |
| keratoconjunctivitis caused | #26 |
| correlated corneal | #26 |
| 100 nylon | #26 |
| statistical decrease | #26 |
| level il4 | #26 |
| conjunctival inflammation | #26 |
| singletreatment groups | #26 |
| diseases ambient | #26 |
| smallincision cataract surgery | #26 |
| adhered fibroblasts | #26 |
| postkeratoplasty glaucoma | #26 |
| tbut tear | #26 |
| 01 topical | #26 |
| rapid epithelialization | #26 |
| symptoms itching | #26 |
| lnfs | #26 |
| wheal diameter | #26 |
| corneal ulcers | #26 |
| 005 immunoreactive | #26 |
| solutions corneal | #26 |
| dmem f12 medium | #26 |
| conclusions improvement | #26 |
| damage adhesion | #26 |
| treatment meibomian | #26 |
| subjects measuring | #26 |
| aureus detected | #26 |
| slit lamp examinations | #26 |
| specific ige positivity | #26 |
| conjunctivitis | #26 |
| eyes topical | #26 |
| density subbasal | #27 |
| factor exacerbation | #27 |
| 005 symptoms | #27 |
| eosinophils fibroblasts | #27 |
| oct prospective | #27 |
| 01 cyclosporine | #27 |
| conjunctival epithelial | #27 |
| epinastine | #27 |
| prescribed topical | #27 |
| antibodies brush | #27 |
| therapy conjunctiva | #27 |
| cytometry chemotaxis | #27 |
| reaction sensation | #27 |
| alpha eosinophils | #27 |
| associations prevalence | #27 |
| interleukin4 polymerase | #27 |
| child cytological | #27 |
| lymphocytes specimens | #27 |
| tear ocular | #27 |
| assay eosinophils | #28 |
| objective scores | #28 |
| severe ocular | #28 |
| provide relief | #28 |
| corneal vivo | #28 |
| 4 5ac | #28 |
| corneal ulceration | #28 |
| chemotactic activity eosinophils | #28 |
| underwent immunohistochemical | #28 |
| solutions ophthalmologic | #28 |
| 2 iol | #28 |
| ophthalmic | #28 |
| eosinophil adherence | #28 |
| prevalence allergic diseases | #28 |
| diseases proliferative | #28 |
| il13 il1beta | #28 |
| conjunctiva dexamethasone | #28 |
| assessment tear | #28 |
| stress atopic | #28 |
| giant papillae | #28 |
| papillae patients | #28 |
| conjunctival epithelial cells | #28 |
| performed morphometric | #29 |
| rosebengal | #29 |
| thermography adolescent | #29 |
| allergic regulation | #29 |
| studies conjunctivitis | #29 |
| sac compared | #29 |
| 5ac mucins | #29 |
| conjunctiva dose | #29 |
| cys treatment | #29 |
| scores schirmer | #29 |
| aged thermography | #29 |
| flare cell | #29 |
| numbers inflammatory | #29 |
| disease periostin | #29 |
| corneal conjunctival | #29 |
| inhibited tranilast | #29 |
| eye mask | #29 |
| ketotifen fumarate | #29 |
| palpebral | #30 |
| ocular surface alterations | #30 |
| fibroblasts protease | #30 |
| syndromes equipment | #30 |
| il2r serum | #30 |
| mucins ophthalmic | #30 |
| dermatitis efficacy | #30 |
| conjunctivitis humans | #30 |
| common adverse reaction | #30 |
| recruitment day | #30 |
| effective artificial | #30 |
| tear ige | #30 |
| eye common | #30 |
| symptoms accompanying | #30 |
| minutes visit | #30 |
| expressed crth2 | #30 |
| conjunctiva cells | #30 |
| specificity tears | #30 |
| infection conjunctival | #30 |
| regrowth observed | #30 |
| inhibitors pollen | #30 |
| conjunctivitis patients | #30 |
| redness eye | #30 |
| tear serum | #30 |
| atopic diagnostic | #30 |
| atopic 10 | #31 |
| worse observed | #31 |
| properties tears | #31 |
| ige negative | #31 |
| disease summarized | #31 |
| pathogenesis corneal | #31 |
| epithelial mucins | #31 |
| hel levels | #31 |
| fibroblasts pcr | #31 |
| levels july | #31 |
| meibomian gland secretion | #31 |
| inflammation atopic | #31 |
| dermatitis purpose | #31 |
| combinations eosinophils | #31 |
| schirmer scores | #31 |
| acuity fva | #31 |
| neutrophils severity | #31 |
| expressed eosinophils | #31 |
| vegf cultured | #31 |
| scores corneal | #31 |
| tear meniscus height | #32 |
| limbus cornea | #32 |
| tgfbeta1 il1beta | #32 |
| sign scores | #32 |
| eye sjögren | #32 |
| deqs | #32 |
| substantial interrater agreement | #32 |
| western blotting effects | #32 |
| analysis tears | #32 |
| conjunctival cells | #32 |
| reduced steroid | #32 |
| keratoconjunctivitis | #32 |
| signs improved | #32 |
| schirmer test values | #32 |
| expressibility | #32 |
| diagnosed dry | #32 |
| prostaglandin cell | #32 |
| atopic skin disease | #33 |
| count prostaglandin | #33 |
| edema correlated | #33 |
| seasonal young | #33 |
| immunoglobulin interferometry | #33 |
| levocabastine | #33 |
| iop induced | #33 |
| numbers quantitative | #33 |
| muc 1 | #33 |
| film break | #33 |
| conclusions confocal | #33 |
| signs evaluated | #33 |
| ige histamine | #33 |
| haze score | #33 |
| 4 grades | #33 |
| allergic double | #33 |
| visante | #33 |
| therapy histamine | #34 |
| clinical signs patients | #34 |
| 10 objective | #34 |
| fibroblasts purpose | #34 |
| 01 effective | #34 |
| eye 10 | #34 |
| alpha fibroblasts | #34 |
| il1beta tgfbeta1 | #34 |
| treatment mgd | #34 |
| intraocular pressure surgery | #34 |
| proteinchip array | #34 |
| bengal staining | #34 |
| eyes corneal | #34 |
| conjunctiva cytokines | #34 |
| fluorometholone glucocorticoids | #34 |
| interrater reproducibility | #35 |
| eye 20 | #35 |
| 6 months conclusion | #35 |
| mucins prospective | #35 |
| adult asthenopia | #35 |
| hypertension tacrolimus | #35 |
| tear stability | #35 |
| objective symptoms | #35 |
| virus capsid antigen | #35 |
| cyclosporine cys | #35 |
| resection 005 | #36 |
| tear samples | #36 |
| vdt users | #36 |
| efficacy groups | #36 |
| severe allergic | #36 |
| anterior scleritis | #36 |
| diseases eosinophil | #36 |
| functional visual acuity | #36 |
| schirmer 1 | #36 |
| eyes acrysof | #36 |
| differential dry | #36 |
| ocular surface inflammation | #36 |
| humans keratoconjunctivitis | #36 |
| measured tear | #36 |
| tear clearance | #36 |
| eyelid skin | #37 |
| scleritis episcleritis | #37 |
| induced iop | #37 |
| recurrence corneal | #37 |
| tenon anesthesia | #37 |
| wellrecognized risk | #37 |
| tears tumor | #37 |
| schirmer 1 test | #37 |
| 002 mmc | #37 |
| tacrolimus 12 | #37 |
| delefilcon | #37 |
| oct effective | #37 |
| laser flarecell meter | #37 |
| contact lens surface | #37 |
| conducted compliance | #37 |
| 002 mitomycin | #38 |
| exhibited correlation | #38 |
| gland lipid | #38 |
| cac japanese | #38 |
| pemirolast | #38 |
| aged olopatadine | #38 |
| phacoemulsification implantation | #38 |
| post cataract | #38 |
| allergic cromolyn | #38 |
| device eye | #38 |
| atopic dry | #39 |
| conjunctiva limbus | #39 |
| tears eye | #39 |
| 005 oct | #39 |
| accommodating intraocular | #39 |
| patients dry eye | #39 |
| degree 20 | #39 |
| response pretreatment | #39 |
| cyclosporine dry | #39 |
| tests diagnostic accuracy | #39 |
| 0001 specimens | #39 |
| cells conjunctiva | #39 |
| solutions patient | #39 |
| infiltration corneal | #39 |
| eye patients | #40 |
| decreased inflammation | #40 |
| tmh | #40 |
| samples eyes | #40 |
| endothelial rejection | #40 |
| subjects specimens | #40 |
| drops corneal | #40 |
| ulcers control | #40 |
| acid chemokine | #40 |
| pharmacology clinical efficacy | #40 |
| biomarkers conjunctiva | #40 |
| α pge2 | #41 |
| treated topical | #41 |
| homologous visual | #41 |
| il1beta vegf | #41 |
| conjunctivitis gpc | #41 |
| treatment dry | #41 |
| vegf il1beta | #41 |
| epitheliopathy | #41 |
| ecp concentrations | #41 |
| eyes superior | #41 |
| stimulate vascular | #41 |
| pollution severe | #41 |
| scans underwent | #42 |
| efficient noninvasive | #42 |
| allergens conjunctivitis | #42 |
| day eye | #42 |
| break time | #42 |
| corneal epithelia | #42 |
| october july | #42 |
| eyelid edema | #43 |
| diseases 2017 | #43 |
| surface years | #43 |
| meniscus treatment | #43 |
| instability decreased | #43 |
| limbus corneal | #43 |
| conjunctival hyperemia | #43 |
| revised 2010 | #43 |
| keratolimbal | #43 |
| hydrocarbons data | #43 |
| rollable | #43 |
| cytology revealed | #43 |
| microscopy central | #43 |
| activated il4 | #44 |
| abovementioned drugs | #44 |
| oct assessment | #44 |
| cautery female | #44 |
| tear meniscus | #44 |
| collagens fibronectin | #44 |
| patients rhinoconjunctivitis | #44 |
| eye 0001 | #44 |
| subjective symptom | #44 |
| tryptase par2 | #44 |
| il1beta il4 | #44 |
| agents keratoconjunctivitis | #44 |
| elasticity patients | #44 |
| epithelial defect | #44 |
| tacrolimus treatment | #44 |
| fourgrade scale | #45 |
| micafungin mcfg | #45 |
| elevation iop | #45 |
| body sensation | #45 |
| metaplasia grade | #45 |
| laser microscopy | #45 |
| inflammation ocular surface | #45 |
| users contact | #45 |
| bovine enteric | #45 |
| signs score | #45 |
| rose bengal staining | #45 |
| correlation inflammation | #45 |
| japan particulate | #45 |
| understanding ocular | #45 |
| fibroblasts expression | #45 |
| metaplasia mucin | #45 |
| surgery uncorrected | #45 |
| 24 seconds | #45 |
| adult chemotaxis | #45 |
| topical tacrolimus treatment | #45 |
| recruiting chemokines | #45 |
| case corneal | #45 |
| fibroblasts eosinophils | #45 |
| superficial punctate keratitis | #45 |
| formation corneal | #45 |
| graded 3 | #45 |
| surface inflammation | #45 |
| 17 japanese patients | #46 |
| suspension effective | #46 |
| staining conjunctival | #46 |
| status ocular | #46 |
| staining inflammatory | #46 |
| seconds controls | #46 |
| conjunctival | #46 |
| efficacy 01 | #46 |
| efficacy combined therapy | #46 |
| graticule | #46 |
| tryptases regulation | #46 |
| posttreatment findings | #46 |
| fluorometholone | #46 |
| corneal cells | #46 |
| surface disease | #46 |
| il13 serum | #46 |
| ulcer score | #47 |
| purpose efficacy | #47 |
| diameter plant | #47 |
| suspension 4 | #47 |
| rate ocular | #47 |
| patients 01 | #47 |
| visante oct | #47 |
| blood level | #47 |
| allergic female histamine | #47 |
| positive muc5ac | #47 |
| muc5ac mrna | #48 |
| dexamethasone anti | #48 |
| complications corneal | #48 |
| enhanced benefits | #48 |
| eyes month | #48 |
| brush cytology specimens | #48 |
| cyclosporine ophthalmic | #48 |
| stimulation chemokine | #48 |
| sac patients | #48 |
| eyelid warming | #48 |
| stromal nerve | #48 |
| implantation acrysof | #48 |
| eosinophils epithelium | #49 |
| visits air | #49 |
| concentrations tears | #49 |
| keratocytes fibroblasts | #49 |
| expression crth2 | #49 |
| cxc chemokine genes | #49 |
| 1cu | #49 |
| adult ca125 | #49 |
| fibroblasts incubated | #49 |
| tacrolimus female | #49 |
| ocular signs | #49 |
| male tears | #49 |
| objective findings | #49 |
| trabeculectomy eyes | #49 |
| measuring corneal | #50 |
| disposable soft | #50 |
| dyes fluorophotometry | #50 |
| meniscus height | #50 |
| ulcers purpose | #50 |
| trabeculectomy mitomycin | #50 |
| inflammation conjunctiva | #50 |
| aged blinking | #50 |
| patient eyes | #50 |
| 4 normal controls | #50 |
| test ocular | #50 |
| total severity score | #50 |
| schirmers test | #50 |
| decreased tear | #50 |
| periostin patients | #51 |
| reduction score | #51 |
| diagnosis dry | #51 |
| members japan | #51 |
| markers atopic | #51 |
| inflammation cataract | #51 |
| effects docosahexaenoic acid | #51 |
| lenses scls | #51 |
| scls | #51 |
| cells brush | #51 |
| crth2 expression | #51 |
| ocular surface cells | #51 |
| reaction vehicle | #52 |
| examination parameters | #52 |
| tears tomography | #52 |
| pcr tgf | #52 |
| severity objective | #52 |
| month initiation | #52 |
| atopic groups | #52 |
| eye normal | #52 |
| eyelid margins | #52 |
| biomarker diseases | #52 |
| stability corneal | #52 |
| inflammation decline | #52 |
| stromal nerves | #53 |
| acuity values | #53 |
| differential eosinophil | #53 |
| bromfenac | #53 |
| chloride bak | #54 |
| vegf protein secretion | #54 |
| 005 month | #54 |
| scores tear | #54 |
| limbic keratoconjunctivitis | #54 |
| presence rsv | #54 |
| suspension treatment | #54 |
| lacrimal glands | #54 |
| obstructive mgd | #54 |
| oxidation adolescent | #54 |
| local cytokine production | #55 |
| adult conjunctivitis | #55 |
| combinedtreatment | #55 |
| ocular signs symptoms | #55 |
| antagonists allergic | #55 |
| epithelial cells expression | #55 |
| aged pollen | #55 |
| surface clinical | #55 |
| conjunctiva drug | #55 |
| atopic enterotoxins | #55 |
| ded adult | #56 |
| specular microscopic | #56 |
| dysfunction atopic | #56 |
| eosinophil cationic | #56 |
| plant pollens | #56 |
| mucin layer | #56 |
| solution placebo | #56 |
| allergies adolescent | #56 |
| atopic patients | #56 |
| topical adolescent | #56 |
| mechanism giant | #56 |
| film ocular | #56 |
| 3 dry | #56 |
| pain photophobia | #56 |
| cornea cyclooxygenase | #56 |
| mucin2 mucin4 | #56 |
| inflammation pge2 | #57 |
| penetrating limbus | #57 |
| accommodating iol | #57 |
| humans interleukin4 | #57 |
| insensible administration | #57 |
| giant papillary conjunctivitis | #57 |
| chemotactic responses | #57 |
| schiff staining | #58 |
| drop treatment | #58 |
| seventyeight eyes | #58 |
| alpha defensins | #58 |
| maximum blood concentration | #58 |
| objective sign | #58 |
| staining tear | #58 |
| papilla formation | #58 |
| tear instability | #59 |
| findings criteria | #59 |
| intraoperative mitomycin | #59 |
| type allergic | #59 |
| pm25 prevalence | #59 |
| disease eyes | #59 |
| daily disposable | #60 |
| diabetic corneal | #60 |
| compared 0001 | #60 |
| syndromes female | #60 |
| pcr severe | #60 |
| mmc 2 | #60 |
| evaluation items | #60 |
| signs severe | #60 |
| release inhibitor | #60 |
| tacrolimus ointment treatment | #60 |
| thermography adult | #61 |
| punctal | #61 |
| nonsteroidal blotting | #61 |
| correlation patients | #61 |
| combination epithelium | #62 |
| amplitude accommodation | #62 |
| eyes 16 | #62 |
| values tended | #62 |
| eotaxin1 expression | #62 |
| total clinical | #62 |
| allergen mediated | #62 |
| expression eyes | #62 |
| prostaglandin patients | #62 |
| specimens histopathologic | #62 |
| micafungin treatment | #63 |
| patient corneal | #63 |
| hypersensitivity japan | #63 |
| oral pilocarpine | #63 |
| conjunctiva patients | #63 |
| corneal erosion | #63 |
| il4 role | #63 |
| chamber body | #63 |
| sac age | #63 |
| corneal stem | #63 |
| ulcer endophthalmitis | #63 |
| dexamethasone production | #64 |
| eye adolescent | #64 |
| il4 culture | #64 |
| factor allergic | #64 |
| density inflammatory | #64 |
| positive mucin | #64 |
| radioimmunoassay respiratory | #64 |
| cornea dry | #64 |
| evaluation corneal | #64 |
| conclusions corneal | #65 |
| live rsv | #65 |
| tears biomarkers | #65 |
| mucins rna | #65 |
| viral radioimmunoassay | #65 |
| dust house | #65 |
| microscope methods | #65 |
| diagnosis therapies | #66 |
| cases atopic | #66 |
| surface epithelial | #66 |
| treatment immunosuppressive agents | #66 |
| layer speed | #66 |
| female fluorophotometry | #67 |
| agents keratoplasty | #67 |
| effects 01 | #67 |
| period oral | #67 |
| persistent epithelial | #67 |
| 003 treatment | #67 |
| cyclosporine eye | #67 |
| time vital | #68 |
| ointment treatment | #68 |
| eye dry | #68 |
| housedust | #68 |
| counter drugs | #69 |
| ophthalmic solutions | #69 |
| occlusion 005 | #69 |
| fibroblasts examined | #69 |
| patients eosinophils | #69 |
| glaucoma graft | #69 |
| aged tears | #69 |
| fibroblasts corneal | #69 |
| schirmer test | #70 |
| visit 4 | #70 |
| rhinoconjunctivitis allergic | #70 |
| 1436 patients | #70 |
| values rose | #70 |
| crth2 receptor | #70 |
| 22 eyes | #70 |
| crth2 pgd2 | #70 |
| drops treatment | #71 |
| factors tears | #71 |
| allergic dermatitis | #71 |
| lenses dry | #71 |
| dust 20 | #71 |
| tear production | #72 |
| bulbar conjunctiva | #72 |
| 16 eyes | #72 |
| glaucoma trabeculectomy | #72 |
| ige eosinophil | #72 |
| fml | #73 |
| fluorophotometry humans | #73 |
| pollution prevalence | #73 |
| extraction conjunctiva | #73 |
| antiallergic agent | #73 |
| pyridines pyrimidinones | #73 |
| surface mucins | #73 |
| liquid conjunctiva | #73 |
| punctate keratopathy | #73 |
| immunosuppressive treatment patients | #73 |
| epithelial structure | #73 |
| tacrolimus patients | #74 |
| evaluation dry | #74 |
| eosinophils expressed | #74 |
| mcfg | #74 |
| agents intraocular | #74 |
| iol acrysof | #74 |
| inflammatory cell numbers | #74 |
| cedar pollen | #75 |
| pilocarpine prospective | #75 |
| dust epidemiologic | #75 |
| 1 month baseline | #75 |
| healthy individuals patients | #75 |
| laser flare | #75 |
| improved infrared | #75 |
| completely controlled | #75 |
| agents interleukin4 | #76 |
| ccchemokine | #76 |
| interleukin4 rna | #76 |
| guidelines allergic | #76 |
| cytology samples | #77 |
| chemical mediator | #77 |
| excision recurrence | #77 |
| studies suspensions | #77 |
| ophthalmological elasticity | #77 |
| surgery technique | #77 |
| slight elongation | #77 |
| capilia | #77 |
| signs treatment | #77 |
| cornea module | #77 |
| lower tear | #77 |
| cytokines stimulate | #77 |
| vegf tgfbeta1 | #77 |
| drops 1 | #78 |
| severity ocular | #78 |
| concentration il2 | #78 |
| concomitant tacrolimus | #78 |
| signs observed | #78 |
| japanese guideline | #78 |
| pollen compared | #78 |
| extended wear | #79 |
| allergic environmental | #79 |
| ocular pain | #79 |
| permeability cornea | #79 |
| inhibitors leupeptin | #79 |
| dry eye | #79 |
| effects corneal | #79 |
| type allergy | #79 |
| glaucoma penetrating | #79 |
| il4 ige | #79 |
| injection reduction | #79 |
| assay epithelial | #80 |
| mediated par2 | #80 |
| medications required | #80 |
| mgd patients | #80 |
| questionnaires tears | #80 |
| vegf concentration | #81 |
| decreased dry | #81 |
| antigens histamine | #81 |
| atopic dermatitis study | #82 |
| cytology performed | #82 |
| patients conjunctivitis | #82 |
| prostaglandin reverse | #82 |
| acrysof iol | #82 |
| caused insufficient | #82 |
| complications lenses | #83 |
| expression corneal | #83 |
| data tacrolimus | #83 |
| patients staphylococcus aureus | #83 |
| dental college | #83 |
| tear lipid | #83 |
| cytokines vegf | #84 |
| papillae | #84 |
| schirmer | #84 |
| correlation corneal | #84 |
| earlier published data | #84 |
| epithelium ocular | #84 |
| hyperemia induced | #85 |
| temperature patients | #85 |
| combined penetrating | #85 |
| alterations basal | #85 |
| scleritis patients | #85 |
| inhibitors tryptases | #85 |
| treatment odds ratio | #85 |
| patients dry | #85 |
| human reverse | #85 |
| 5 grades | #85 |
| 18 pg | #85 |
| patients eyelid | #86 |
| discharge evaluated | #86 |
| acuity accommodation | #86 |
| inflammation eye | #86 |
| pharmacologic intervention | #86 |
| edema scores | #86 |
| 284 years | #86 |
| sligkv | #86 |
| daily outpatient | #86 |
| tacrolimus reduced | #87 |
| tacrolimus young | #87 |
| detection limit assay | #87 |
| confocal ophthalmic | #87 |
| tears | #88 |
| cells keratocytes | #88 |
| regulation muc5ac | #88 |
| post keratoplasty | #88 |
| daily weather conditions | #88 |
| sclera surgical | #88 |
| disease conjunctiva | #88 |
| findings severe | #89 |
| assessment dry | #89 |
| tears visual | #89 |
| seasonal perennial | #89 |
| tryptase inhibitors | #89 |
| eyes 30 | #89 |
| cytocentrifuge preparations | #90 |
| decrease corneal | #90 |
| temperature cornea | #90 |
| dressings chronic | #90 |
| tears adult | #90 |
| early ocular | #90 |
| lower corneal | #90 |
| months signs | #90 |
| glands microscopy | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| techniques trabeculectomy | #92 |
| eye corneal | #92 |
| procedures phacoemulsification | #92 |
| laser cell | #92 |
| exposure japan | #92 |
| treatment noninfectious | #93 |
| stromal corneal | #93 |
| conjunctival specimens | #93 |
| regulation muc1 | #93 |
| 7 visit | #93 |
| tears administration | #93 |
| preschool conjunctiva | #93 |
| eye cataract surgery | #93 |
| solutions tears | #93 |
| drug fibroblasts | #93 |
| patients correlation | #93 |
| 005 complications | #93 |
| exposure exhaust | #94 |
| pollution weather | #94 |
| pgd2 crth2 | #94 |
| case allergic | #94 |
| classification pathogenesis | #94 |
| reaction physical | #94 |
| eosinophils patients | #95 |
| twentyeight eyes | #95 |
| studies tears | #95 |
| eye higher | #95 |
| induced pgd2 | #95 |
| relevant factor | #95 |
| score objective | #96 |
| higher eyes | #96 |
| protein eosinophilia | #96 |
| study cyclosporine | #96 |
| 128 eyes | #96 |
| staining fluorescein | #96 |
| cells hel | #97 |
| 4 alterations | #97 |
| production pge2 | #97 |
| treatment ecp | #97 |
| 1month treatment | #97 |
| eyes study | #98 |
| meniscus patients | #98 |
| staining schirmer | #98 |
| vdts | #98 |
| eye tear | #98 |
| eyes positive | #98 |
| surgery 6 months | #99 |
| 005 recurrence | #99 |
| pseudophakic patients | #99 |
| management ocular | #99 |
| japan post | #99 |
| cytology evaluation | #99 |
| solution improved | #99 |
| equivalent 4 | #99 |
| ointments tacrolimus | #100 |
| confocal scanning | #100 |
| allergic atopic | #100 |
| corneal abnormalities | #100 |
| postoperatively statistically | #100 |
| cells severity | #100 |
| ulcer patient | #100 |
| conjunctiva corneal | #100 |
| local pattern | #100 |
| terminals contact | #100 |
| pathogenesis atopic | #101 |
| fibroblasts 2 | #101 |
| eyes 10 | #101 |
| effects tranilast | #102 |
| disease classified | #102 |
| keratolimbal allograft | #102 |
| pathogenesis allergic | #102 |
| severe atopic | #102 |
| agents conjunctivitis | #102 |
| therapy conjunctival | #102 |
| prevalence dry | #103 |
| mediated protease | #103 |
| chemotaxis experiments | #103 |
| subjective comfort | #103 |
| washing solution | #103 |
| groups dry | #104 |
| differences ocular | #104 |
| topic premedication | #104 |
| patients bf | #104 |
| events scores | #104 |
| topical cyclosporine | #104 |
| values vital | #104 |
| allergic cytokines | #104 |
| tears young | #104 |
| syndrome epstein | #104 |
| inflammation diagnosis | #105 |
| wearing contact | #105 |
| conjunctival impression cytology | #105 |
| child conjunctival | #105 |
| aged amnion | #105 |
| baseline initiation | #105 |
| role staphylococcal | #105 |
| microscopy evaluation | #106 |
| 14 eyes | #106 |
| pressure keratoplasty | #106 |
| conjunctiva cornea | #106 |
| adhesion fibroblasts | #106 |
| parameters ocular | #106 |
| corneal keratocytes | #107 |
| superficial punctate | #107 |
| eotaxin1 | #107 |
| patients ded | #107 |
| topical tacrolimus | #108 |
| lipid layer | #108 |
| conjunctiva | #108 |
| induces chemotaxis | #108 |
| scores symptoms | #108 |
| resins aged | #108 |
| levels radioimmunoassay | #108 |
| film instability | #108 |
| dry mouth symptoms | #108 |
| acuity acrylic | #108 |
| 4 dry | #109 |
| effects dha | #109 |
| corneal inflammatory | #109 |
| tear evaporation | #109 |
| asian dust | #109 |
| il4 human | #109 |
| level tacrolimus | #109 |
| japanese guidelines | #110 |
| lacrimal salivary | #110 |
| dysfunction mgd | #110 |
| steroids administration | #110 |
| controls inflammatory | #110 |
| eyes 9 | #110 |
| increased evaporation | #110 |
| conjunctival epithelium | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| eye camera | #112 |
| vcam1 antibody | #112 |
| pcr rsv | #113 |
| dibenzoxepins | #113 |
| anterior segment inflammation | #113 |
| strabismus surgery | #113 |
| papillary conjunctivitis | #113 |
| solutions platelet | #113 |
| incision cataract | #114 |
| eye irritation | #114 |
| layer patients | #114 |
| diagnosed allergic | #114 |
| grading scores | #114 |
| lesions atopic | #114 |
| cholinergic treatment | #115 |
| seconds 0001 | #115 |
| conjunctival cell | #115 |
| male mucin | #115 |
| 13 eyes | #115 |
| goblet cell density | #115 |
| allergic eye | #115 |
| findings severity | #115 |
| sjögrens syndrome patients | #115 |
| edition revised | #116 |
| selective histamine | #116 |
| viscosupplements aged | #117 |
| cooling increased | #117 |
| samples stained | #117 |
| patients seasonal | #117 |
| ophthalmology prevalence | #117 |
| metaplasia mucins | #117 |
| asia dust | #117 |
| molecule1 interleukin4 | #118 |
| sag genes | #118 |
| immunologic receptors prostaglandin | #118 |
| effects docosahexaenoic | #118 |
| generation pge2 | #118 |
| chemotaxis induced | #119 |
| revealed higher | #119 |
| 39 mmhg | #119 |
| week 005 | #119 |
| skin elasticity | #119 |
| acuity distance | #119 |
| iop observed | #119 |
| topical steroids | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| mitomycinc mmc | #121 |
| mitomycin ophthalmic | #121 |
| distance corrected | #121 |
| levels histamine | #121 |
| soft lenses | #121 |
| chronic allergic | #122 |
| collagen conjunctiva | #123 |
| adult conjunctiva | #123 |
| artificial tear | #123 |
| titers ebv | #123 |
| male ointments | #123 |
| eosinophils cell | #124 |
| area corneal | #124 |
| activity corneal | #125 |
| conjunctival tissues | #125 |
| month reduced | #126 |
| damage severe | #126 |
| proteaseactivated receptor2 | #126 |
| nerves studied | #127 |
| 05ng | #127 |
| patients atopic | #127 |
| subjects vivo | #127 |
| gamma increase | #128 |
| 9 genes | #128 |
| soft contact lenses | #128 |
| elisa levels | #129 |
| 361 ± | #129 |
| acds | #129 |
| combination steroids | #129 |
| fibroblast viability | #129 |
| fva | #130 |
| patients insignificant | #130 |
| functional visual | #130 |
| disease cornea | #131 |
| antigen hladr | #131 |
| eye drop | #132 |
| management allergic | #132 |
| cataract phacoemulsification | #132 |
| resection severe | #132 |
| 5ac | #132 |
| eyes fluorescein | #132 |
| proteins mucin | #133 |
| skin water | #133 |
| keratoplasty adult | #133 |
| gene transcription levels | #133 |
| 19 normal subjects | #133 |
| treated tacrolimus | #133 |
| surface examination | #134 |
| acrylic iol | #134 |
| density negative | #134 |
| normal conjunctival | #134 |
| pcr hla | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| ophthalmological dry | #137 |
| antiallergic properties | #137 |
| dry eye patients | #137 |
| severity 10 | #137 |
| eosinophil adhesion | #137 |
| ocular surface | #137 |
| iol groups | #138 |
| eosinophil cationic protein | #138 |
| asian dust storms | #138 |
| authors technique | #139 |
| allergic dogs | #139 |
| protein ecp | #139 |
| ratio remission | #139 |
| suppressed pretreatment | #140 |
| inflammation prostaglandin | #141 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| findings upper | #142 |
| interleukin1 interleukin13 | #142 |
| improvements symptom | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| studies scleritis | #144 |
| 52 mmhg | #144 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| recordable | #145 |
| eye syndromes | #145 |
| symptoms ocular | #145 |
| specimens patient | #145 |
| fibroblasts alpha | #146 |
| virus pathogen | #146 |
| human conjunctiva | #146 |
| findings adolescent | #146 |
| underwent evaluation | #146 |
| reticular basement membrane | #146 |
| eye clinical | #146 |
| schiff reaction | #146 |
| impression cytology | #147 |
| hne 4 | #147 |
| 263 years | #147 |
| required type | #147 |
| dscg | #147 |
| diagnosis atopic | #147 |
| dynamic visual acuity | #148 |
| increased goblet | #148 |
| ulcer drug | #148 |
| 0001 corneal | #148 |
| cationic protein | #149 |
| japan phenotype | #149 |
| concentration tacrolimus | #149 |
| patients allergic | #149 |
| suspension based | #149 |
| intraocular lens iol | #149 |
| fibroblasts production | #149 |
| quantitative evaluation | #149 |
| pyrimidinones treatment | #150 |
| inflammatory cells | #150 |
| japanese cedar pollen | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| tacrolimus treated | #152 |
| par2 reverse | #152 |
| postoperative secondary | #152 |
| 28 surgery | #153 |
| increased fibroblasts | #153 |
| artificial tears | #153 |
| eyes 11 | #153 |
| induced eotaxin | #153 |
| symptoms objective | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| association pm25 | #156 |
| chemokine expression | #156 |
| alcon | #156 |
| eyelids female | #156 |
| inflammatory ocular | #157 |
| analysis prostaglandin | #157 |
| lipid infiltration | #157 |
| greater inflammation | #157 |
| values improved | #157 |
| ointments skin | #157 |
| pcr increase | #157 |
| rates untreated | #157 |
| acuities | #158 |
| japan included | #158 |
| trial tacrolimus | #158 |
| surface status | #158 |
| weeks adverse | #159 |
| immunological characteristics | #159 |
| 3 boys | #159 |
| study inflammation | #160 |
| muc16 | #161 |
| elevation study | #161 |
| acid schiff | #161 |
| thirtysix eyes | #161 |
| mucin 5ac | #161 |
| 28 female | #161 |
| chemokines production | #161 |
| male meibomian | #162 |
| bromobenzenes | #162 |
| surgery topical | #162 |
| distance visual acuity | #162 |
| 326 years | #162 |
| twentynine eyes | #163 |
| efficacy tacrolimus | #163 |
| il1beta il2 | #163 |
| oxidative stress status | #163 |
| studied 21 | #163 |
| visit 7 | #163 |
| prevalence ocular | #163 |
| olopatadine | #163 |
| 002 treatment | #164 |
| steroid anti | #164 |
| soft contact | #164 |
| 30ng | #164 |
| spt positive | #164 |
| patients topical | #164 |
| purpose reported | #164 |
| biological dressings | #165 |
| production prostaglandin | #165 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| pgd2 induced | #166 |
| cytokines allergic | #167 |
| eosinophils higher | #167 |
| tacrolimus ointment | #167 |
| ulcers erosions | #168 |
| males 5 | #168 |
| seldi | #169 |
| local allergic | #169 |
| eotaxin chemokine | #169 |
| patients postsurgical | #169 |
| 12 males | #169 |
| studies tacrolimus | #169 |
| treating refractory | #169 |
| steroidal blotting | #169 |
| expression chemokines | #170 |
| management enzyme | #171 |
| conjunctiva conjunctival | #171 |
| status inflammation | #171 |
| subbasal nerve | #172 |
| palisades | #173 |
| fibroblasts fibroblast | #173 |
| subjective symptoms | #174 |
| standard conventional | #174 |
| slit lamp | #174 |
| distance acuity | #174 |
| vivo confocal | #174 |
| pcr flow | #174 |
| status oxidative | #174 |
| postkeratoplasty | #175 |
| 34 eyes | #175 |
| evaluated symptoms | #176 |
| homologous molecule | #176 |
| subbasal | #177 |
| study longterm outcomes | #177 |
| dust extract | #177 |
| treatment corneal | #177 |
| aldehydes biomarkers | #177 |
| reduction intraocular pressure | #178 |
| acrysof | #178 |
| tryptase | #178 |
| strabismus adolescent | #178 |
| mild 2 | #178 |
| endophthalmitis female | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| japan young adult | #180 |
| migration eosinophils | #180 |
| ceramides child | #180 |
| 4 female | #180 |
| dyes follow | #180 |
| compared eye | #180 |
| myopic regression | #180 |
| normal control patients | #181 |
| cutometer | #181 |
| lipid study | #181 |
| blepharitis | #183 |
| lipoproteins micafungin | #183 |
| serum il4 | #183 |
| male radioallergosorbent | #184 |
| mucin4 mucins | #185 |
| igg virus | #185 |
| human lymphocyte antigen | #185 |
| examined parameters | #186 |
| nerve prospective | #186 |
| therapy corneal | #186 |
| par2 mrna | #187 |
| corneal fibroblasts | #187 |
| suspensions administration | #187 |
| atopic eosinophils | #187 |
| drug fibroblasts humans | #187 |
| efficacy topical | #187 |
| eye symptoms | #188 |
| corneal sensitivity | #188 |
| 19 eyes | #188 |
| il13 increased | #188 |
| seconds patients | #189 |
| production stromal | #189 |
| allergic cross | #189 |
| sensitivity regulation | #189 |
| levels 33 | #190 |
| infiltrating eosinophils | #191 |
| effects diesel | #191 |
| tear break | #191 |
| assisted infrared | #191 |
| improvement subjective | #192 |
| therapeutic study | #193 |
| allergic rhinoconjunctivitis | #193 |
| controls vivo | #193 |
| 26 eyes | #194 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| reactivation epstein | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| interleukin4 production | #197 |
| eyes 21 | #197 |
| tear film stability | #197 |
| 80 allergens | #197 |
| methods primary | #197 |
| treatment topical | #197 |
| elisa performed | #198 |
| 28 eyes | #198 |
| tears time | #198 |
| combination topical | #198 |
| pollen prospective | #199 |
| effects topical | #199 |
| photorefractive keratectomy | #201 |
| perennial allergic | #201 |
| mcp1 ip10 | #201 |
| pollen allergic | #201 |
| preservative free | #201 |
| rsv infected | #202 |
| receptor homologous | #202 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| eosinophils neutrophils | #203 |
| pge2 human | #204 |
| differences iop | #204 |
| vcam1 icam1 | #204 |
| grade scale | #204 |
| ova alum | #204 |
| eyes 005 | #205 |
| inflammatory allergic | #205 |
| time tbut | #206 |
| disease dry | #206 |
| minutes 8 | #206 |
| eyes cataract | #206 |
| disease acd | #206 |
| glands middle | #207 |
| count cornea | #207 |
| ecp levels | #207 |
| pressure lens | #207 |
| crth2 | #207 |
| formation giant | #207 |
| mammalian milk | #208 |
| fluorescein fluorescent | #208 |
| tears aged | #208 |
| size contact | #208 |
| uncorrected corrected | #209 |
| analysis pm25 | #209 |
| human allergic | #210 |
| treatment allergic | #210 |
| month reduction | #210 |
| antiallergic drug | #211 |
| refractory conventional | #211 |
| oct diagnosis | #211 |
| combination tests | #212 |
| iol patients | #212 |
| tacrolimus combination | #212 |
| inflammation injection | #212 |
| treated refractory | #213 |
| chamber anti | #213 |
| conjunctiva eye | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| nuclear cataract | #219 |
| expressions higher | #219 |
| august october | #220 |
| metabolism lysine | #220 |
| conjunctival biopsy | #220 |
| tranilast | #220 |
| findings inflammation | #221 |
| conjunctivitis acute | #221 |
| combined therapy | #222 |
| samples correlated | #222 |
| level ambient | #222 |
| diseases dry | #222 |
| twentyfour eyes | #222 |
| cells crth2 | #222 |
| iop corneal | #224 |
| 26 control subjects | #224 |
| symptoms short | #224 |
| sensitivity measurements | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| corneal clarity | #228 |
| treatment 3 months | #228 |
| eyes adult | #228 |
| followup cases | #229 |
| itching | #229 |
| treatment superior | #230 |
| eye signs | #230 |
| corrected distance | #230 |
| activity eosinophils | #231 |
| 30 eyes | #231 |
| exhaust particles | #231 |
| examined level | #232 |
| events initiation | #232 |
| alpha defensin | #232 |
| scleral flap | #232 |
| anti allergic | #233 |
| proteinchip | #233 |
| 791 patients | #233 |
| cyclosporine treatment | #233 |
| concomitantly administered | #233 |
| dye staining | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| corneal disease | #236 |
| quantitatively evaluate | #236 |
| specimens patients | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| studied subjects | #240 |
| tool quantitative | #240 |
| diagnostic abilities | #240 |
| proliferative lesions | #240 |
| bf patients | #241 |
| eyes ocular | #241 |
| cell chemotactic | #242 |
| cromolyn sodium | #242 |
| surface lipid | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| subjects males | #247 |
| eye drops | #247 |
| equivalent 2 | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| labeling intercellular | #251 |
| response prostaglandin | #251 |
| seasonal allergic | #252 |
| leukocyte child | #252 |
| syndrome tears | #252 |
| subjective objective | #252 |
| males 13 | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| muc | #255 |
| improved vision | #255 |
| corneal female | #255 |
| dexamethasone inhibition | #256 |
| stability positive | #256 |
| rantes expression | #256 |
| treating severe | #257 |
| disease corneal | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| role histamine | #260 |
| eosinophil infiltration | #260 |
| month treatment | #260 |
| additional medications | #260 |
| eyes control | #260 |
| expression rsv | #261 |
| human transcription | #261 |
| smaller normal | #262 |
| h1 antagonist | #262 |
| severity adverse | #264 |
| aged mucin | #264 |
| immunohistochemistry increased | #264 |
| 1 month treatment | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| eyelid diseases | #266 |
| controls p0001 | #266 |
| signs blood | #267 |
| data weekly | #267 |
| studied production | #268 |
| patients sjögren syndrome | #268 |
| treatment atopic | #268 |
| microscopy negative | #268 |
| respiratory syncytial virus | #268 |
| sodium drug | #269 |
| computer terminals | #270 |
| h1 histamine | #270 |
| aged aldehyde | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| 13 males | #273 |
| improved visual acuity | #273 |
| aldose reductase inhibitor | #273 |
| studies stevens | #274 |
| epithelium endothelium | #274 |
| combination eosinophils | #274 |
| concentration quantitative | #274 |
| meibomian gland dysfunction | #275 |
| patients sjögren | #277 |
| tear breakup time | #277 |
| meibomian gland | #277 |
| individuals pcr | #278 |
| tbut | #278 |
| grading score | #278 |
| 13 females | #279 |
| eyes 14 | #279 |
| 0001 diagnosis | #279 |
| bloodaqueous barrier | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| required provide | #281 |
| 10 seconds | #281 |
| disease purpose | #282 |
| cautery | #282 |
| expressed th2 | #282 |
| ige positive | #284 |
| gland dysfunction | #284 |
| amniotic membrane | #285 |
| contralateral eye | #285 |
| atopic | #286 |
| seasons adolescent | #286 |
| th2 cytokines | #287 |
| layer adult | #288 |
| cases refractory | #288 |
| study tacrolimus | #289 |
| adult alkylating | #289 |
| entericcoated | #291 |
| eyedrops | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| treatment 01 | #294 |
| exponential equation | #294 |
| new antifungal | #294 |
| single therapy | #295 |
| levels ige | #295 |
| serum periostin | #295 |
| hyperemia | #297 |
| surgery statistically | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| rose bengal | #300 |
| severity diagnosis | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| cobblestone | #303 |
| moderate 3 | #303 |
| assessed based | #303 |
| photophobia | #304 |
| scanning laser | #304 |
| operation patient | #305 |
| scores worse | #305 |
| initiation treatment | #305 |
| piperidines treatment | #306 |
| eczema severity | #306 |
| assessed 4 | #307 |
| membrane patch | #307 |
| gel application | #308 |
| evaluation groups | #309 |
| interleukin13 interleukin2 | #309 |
| 10 normal subjects | #309 |
| comfort level | #310 |
| compared simple | #310 |
| inflammatory cell | #310 |
| cytology specimens | #311 |
| 12 eyes | #311 |
| regard age | #311 |
| slitlamp examination | #311 |
| treatment seasonal | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| eye adult | #315 |
| aged staining | #315 |
| 19 normal | #316 |
| child corneal | #316 |
| interferometry light | #317 |
| cells cornea | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| dermatitis clinical | #320 |
| fluorophotometry | #320 |
| prospective singlearm study | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| 15 30 minutes | #325 |
| eyes 19 | #325 |
| icam1 vcam1 expression | #326 |
| 095 ± | #326 |
| chemokine concentrations | #327 |
| surgery diabetic | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| pressure ocular | #331 |
| treatment 2 weeks | #331 |
| receptors il2r | #332 |
| dry eye disease | #332 |
| leukocyte coculture | #333 |
| cornea diagnostic | #335 |
| eye treated | #335 |
| values daily | #335 |
| proprietary | #336 |
| male staphylococcal | #337 |
| 27 eyes | #337 |
| corneal epithelial | #337 |
| daily wear | #339 |
| signs clinical | #339 |
| levels epithelial | #341 |
| eyes 27 | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| measurements treatment | #347 |
| corneal infection | #347 |
| expression eosinophils | #348 |
| eyes 13 | #348 |
| induced elevation | #348 |
| test values | #350 |
| surgery eye | #350 |
| surface diseases | #352 |
| contrast visual | #352 |
| iop elevation | #353 |
| weekly average | #354 |
| expression allergic | #354 |
| temperature infrared | #355 |
| incidence allergic | #355 |
| examination serum | #356 |
| choroidal detachment | #356 |
| patients allergy | #357 |
| tear film | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| months conventional | #359 |
| tacrolimus tumor | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| studies sclera | #368 |
| treatment ocular | #368 |
| plant pollen | #368 |
| function laser | #368 |
| corneae male | #369 |
| eyes 17 | #370 |
| postoperative adhesion | #370 |
| mucin1 mucin2 | #370 |
| systemic control | #371 |
| inhibitors epithelium | #372 |
| cryptomeria japonica | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| cornea female | #375 |
| assessment severe | #375 |
| improvement local | #375 |
| retina tomograph | #376 |
| extraction cell | #376 |
| 10 normal | #377 |
| higher human | #377 |
| 4 lower | #377 |
| phacoemulsification prospective | #377 |
| levels atopic | #377 |
| tarsal | #378 |
| count child | #378 |
| treatment eyes | #378 |
| stimulation tnf | #380 |
| mitomycin | #380 |
| cornea eye | #381 |
| corneal inflammation | #381 |
| negative serum | #382 |
| inflammation epithelial | #383 |
| pollinosis | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| corneal epithelial cells | #386 |
| ocular diseases | #386 |
| surgery 13 | #388 |
| decrease inflammatory | #388 |
| surface alterations | #388 |
| limit assay | #388 |
| cells vehicle | #389 |
| healing adult | #389 |
| severity incidence | #390 |
| sde | #390 |
| patients proteins | #391 |
| antiallergic | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| applied 5 | #395 |
| 44 eyes | #395 |
| chronic ocular | #395 |
| relative percentages | #396 |
| techniques interleukin4 | #396 |
| opacity corneal | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| remission based | #400 |
| declaration helsinki | #400 |
| eyes severe | #401 |
| modified boyden | #401 |
| rays male | #402 |
| sedating humans | #403 |
| measurements oct | #404 |
| vogt | #404 |
| cells allergic | #404 |
| weather air | #404 |
| prospective controlled study | #405 |
| reproducibility surface | #406 |
| patients epithelial | #406 |
| improved diagnosis | #407 |
| 137 years | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| acids fibroblasts | #412 |
| eyes 15 | #412 |
| specific total | #412 |
| confocal | #412 |
| counts 1 | #413 |
| allergic reaction | #413 |
| 3 months treatment | #413 |
| keratocytes | #414 |
| limbal | #416 |
| postoperative inflammation | #416 |
| central cornea | #418 |
| penetrating keratoplasty | #418 |
| chemokine ccl11 | #419 |
| speed resolution | #419 |
| patients comfort | #419 |
| mucin4 | #419 |
| sjögren syndrome | #420 |
| ophthalmologist | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| trabeculectomy visual | #430 |
| production 4 | #430 |
| staining score | #431 |
| rhinoconjunctivitis | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| performed immunohistochemistry | #437 |
| cedrus | #437 |
| 5 women | #438 |
| methods eye | #438 |
| regulation eye | #438 |
| commercial tests | #439 |
| foldable | #440 |
| interleukin4 il4 | #440 |
| subjects studied | #440 |
| fluorescein dye | #441 |
| vmr | #441 |
| regulation chemokine | #441 |
| landolt | #441 |
| females normal | #442 |
| adult aldehydes | #442 |
| anti vcam1 | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| 30 serum | #450 |
| male 4 | #450 |
| eye eyes | #451 |
| keratoplasty | #452 |
| wash | #452 |
| versus vehicle | #453 |
| ketotifen | #453 |
| antagonists sedating | #453 |
| response allergens | #454 |
| surface disorder | #454 |
| normal patients | #454 |
| vivo confocal microscopy | #454 |
| ophthalmic nerve | #455 |
| production clearance | #455 |
| water evaporation | #455 |
| 8 genes | #455 |
| humans keratoplasty | #456 |
| agonists pilocarpine | #456 |
| ocular risk | #457 |
| normal controls patients | #457 |
| amnion cell | #457 |
| outpatient visits | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| keratoplasty penetrating | #462 |
| test evaluation | #462 |
| hel | #466 |
| fibroblasts tgf | #467 |
| unpaired ttest | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| diagnosis rate | #476 |
| hladr expression | #476 |
| 13 mmhg | #478 |
| fibroblasts primary | #478 |
| pollen seasons | #478 |
| height measurement | #480 |
| reduce clinical | #480 |
| newly formed vessels | #480 |
| subjects eyes | #481 |
| examined prospective | #482 |
| interleukin 13 | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| shortterm study | #490 |
| myopia photorefractive | #490 |
| disodium cromoglycate | #493 |
| prolonged inflammation | #495 |
| acuity intraocular | #495 |
| ebv reactivation | #495 |
| corneal | #498 |
| months eyes | #498 |
| il2 tumor | #499 |
| stain positive | #499 |
| exposure diesel | #499 |
| lens iol | #500 |
| silicone hydrogel | #500 |
| symptoms efficacy | #501 |
| infections viral | #501 |
| treatment eye | #502 |
| studies status | #502 |
| pge2 cox2 | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| 2 daily | #505 |
| eye position | #505 |
| inflammatory status | #506 |
| correlate severity | #506 |
| airborne particulate matter | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| male water | #519 |
| inhibition production | #519 |
| observed baseline | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| 01 | #522 |
| chemoattractant receptor | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| studies trabeculectomy | #525 |
| dinoprostone epithelial | #525 |
| trabeculectomy | #527 |
| studies cornea | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| itchy | #531 |
| rhodanine | #531 |
| ocular symptoms | #535 |
| serum antigen | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| patients cataract | #538 |
| total hydrocarbons | #538 |
| sac | #539 |
| dependent migration | #539 |
| placebo tablets | #540 |
| capsular bag | #540 |
| visit 6 | #541 |
| 80 anterior | #541 |
| administration topical | #542 |
| cases flow | #542 |
| infrared radiation | #543 |
| 20 normal | #543 |
| 6 male | #544 |
| ebv nuclear antigen | #546 |
| production cultured | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| film layer | #550 |
| prospective comparative study | #550 |
| cryptomeria | #552 |
| il‐4 | #552 |
| effects cooling | #553 |
| disease complicated | #553 |
| engorgement | #554 |
| genechip | #555 |
| disease ded | #555 |
| fibroblasts response | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| transplantation combined | #558 |
| density assessed | #558 |
| methods thirty | #559 |
| diesel exhaust particles | #559 |
| ocular infections | #560 |
| differentiation inflammatory | #560 |
| eyes iop | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| 16 age | #569 |
| count corneal | #569 |
| levels il4 | #570 |
| cultured corneal | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| 4 mrna | #580 |
| iop eyes | #580 |
| fibrosis fluorescent | #582 |
| lesions normal | #582 |
| apparatus male | #582 |
| tnfalpha stimulation | #584 |
| department ophthalmology | #584 |
| increase vegf | #584 |
| symptoms scores | #588 |
| intraocular male | #589 |
| corneal epithelium | #589 |
| patients csa | #589 |
| female humans allergic | #589 |
| hladr antigen | #589 |
| induced 4 | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| assay eye | #597 |
| findings evaluated | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| topical adult | #609 |
| inflammation status | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| patients complained | #615 |
| antagonists humans | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| ocular allergy | #617 |
| grades 0 | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| years studied | #625 |
| glaucoma medications | #625 |
| lamp examination | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| redness | #636 |
| patients tacrolimus | #636 |
| burning sensation | #636 |
| corneal haze | #636 |
| total immunoglobulin | #638 |
| based severity | #639 |
| eosinophils | #639 |
| contact lenses | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| months 01 | #643 |
| performed modified | #643 |
| symptoms signs | #643 |
| observed follow | #644 |
| fibrosis actins | #645 |
| mellitus double | #645 |
| patients healthy volunteers | #650 |
| 2 females | #651 |
| viscosupplements | #651 |
| expression administration | #651 |
| analysis existence | #654 |
| eosinophils flow | #654 |
| diseases methods | #656 |
| lacrimal | #657 |
| comfortable | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| lens wearers | #664 |
| treatment 0001 | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| 10 age | #669 |
| viruses acute | #669 |
| damage scores | #669 |
| stimulation rna | #672 |
| cedar | #672 |
| humans lacrimal | #673 |
| 11 males | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| test methods | #681 |
| adherence anti | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| fibronectin cell | #684 |
| stainings | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| cells eye | #694 |
| atopic female humans | #694 |
| 1 test | #695 |
| inhibition expression | #697 |
| early antigen | #697 |
| levels detection | #700 |
| cromolyn | #700 |
| objective assessments | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| key cells | #718 |
| 5 eyes | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| 11 male | #730 |
| followup treatment | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| reductase inhibitor | #737 |
| symptoms 5 | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| unpaired test | #746 |
| blood eosinophils | #746 |
| definition classification | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| daily weather | #751 |
| cornea corneal | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| trabeculectomy treatment | #763 |
| topical aged | #763 |
| intraocular lens implantation | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| oligopeptides rna | #769 |
| pathogenesis severe | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| levels prostaglandin | #783 |
| role allergic | #783 |
| fluorescein fluoresceins | #784 |
| limbus corneae | #784 |
| treatment 1 | #785 |
| purpose analyze | #785 |
| blinking | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| eyes normal | #792 |
| lenses intraocular | #792 |
| tacrolimus | #793 |
| techniques laminin | #793 |
| increased epithelial | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| report efficacy | #801 |
| positive linear | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| receptors ccr3 | #813 |
| mucin | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| aged cell | #820 |
| concentration dose | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| preoperative level | #834 |
| lymphocytes compared | #834 |
| cases follow | #835 |
| surgical outcome | #835 |
| pachymetry | #840 |
| patients operation | #841 |
| individuals patients | #841 |
| implantation intraocular | #842 |
| symptoms improved | #843 |
| ocular adolescent | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| exhaust | #848 |
| levels air | #848 |
| 2 weeks treatment | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| cell area | #855 |
| purpose prospectively | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| thiazolidines | #865 |
| histamine h1 | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| 01 compared | #874 |
| patients eyes | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| h1 antagonists | #880 |
| benzamidine | #880 |
| evaluation early | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| bleb | #887 |
| patients condition | #887 |
| specular | #890 |
| 114 years | #894 |
| respiratory syncytial | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| decreased baseline | #905 |
| benzophenones | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| 8 males | #928 |
| treatment symptoms | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| epithelialization | #937 |
| beta1 tumor | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| cytokines epithelial | #941 |
| symptoms evaluated | #941 |
| normal 1 | #943 |
| humans muscarinic | #946 |
| factor production | #946 |
| wheal | #947 |
| radioallergosorbent test | #949 |
| mgd | #949 |
| seasons young | #950 |
| humans lenses | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| scanning confocal | #957 |
| 2 moderate | #957 |
| singleagent therapy | #959 |
| aldose | #959 |
| 3 eyes | #959 |
| endpoint baseline | #960 |
| sedating | #961 |
| intracellular infection | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| observed conclusions | #994 |
| tenon | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| blink | #1017 |
| 1 2 weeks | #1017 |
| normal volunteers | #1019 |
| impression | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| 045 ± | #1040 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| lysine 4 | #1044 |
| cells fibroblasts | #1044 |
| concomitantly | #1045 |
| treatment skin | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| pollution risk | #1067 |
| disposable | #1067 |
| staphylococcal enterotoxin | #1067 |
| noninfectious | #1070 |
| goblet cell | #1071 |
| acuity patients | #1071 |
| immunocytochemical study | #1073 |
| effective treating | #1075 |
| months corrected | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| ade | #1080 |
| syncytial virus | #1080 |
| expression icam1 | #1082 |
| allergic inflammatory | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| cultures human | #1133 |
| clinical findings | #1133 |
| assay fibroblasts | #1133 |
| treatment objective | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| healthy eyes | #1140 |
| visual acuities | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| p0035 | #1146 |
| 4 daily | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| cornea | #1173 |
| glands sjogren | #1173 |
| fibronectins fibrosis | #1189 |
| immune mechanisms | #1189 |
| ophthalmological female | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| study eyes | #1286 |
| aged substance | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| higher severe | #1316 |
| chemokines chemotaxis | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| 830 | #1322 |
| ccl11 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| female glucocorticoids | #1399 |
| 18 eyes | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| diseases diagnosis | #1413 |
| proteaseactivated receptor | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| haze | #1444 |
| corneal neovascularization | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| bulbar | #1502 |
| studies suture | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| staining | #1514 |
| female fluorescein | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| ortho aminobenzoates | #1602 |
| preservative | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| syncytial | #1663 |
| 10 healthy controls | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| outcome visual | #1713 |
| disease defined | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| central corneal | #1741 |
| cytology | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| eosinophil | #1828 |
| 15 minutes | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| shield | #1860 |
| comparative evaluation | #1860 |
| tnfalpha production | #1862 |
| ari | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| cataract surgery | #1893 |
| aphakia | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| device treatment | #1972 |
| comfort | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| allergens animals | #2067 |
| versus normal | #2067 |
| ambient air pollution | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| endopeptidases serine | #2137 |
| docosahexaenoic acid | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| production inhibited | #2164 |
| curve reproducibility | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| aged mitomycin | #2192 |
| diseases female | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| vital | #2246 |
| rater agreement | #2246 |
| pollens | #2247 |
| scores correlated | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| aged nitrogen | #2415 |
| ophthalmology | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| enteric coated | #2498 |
| fungal female | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| flare | #2573 |
| male polymerase | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| eosinophilia female | #2629 |
| postsurgical | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| total ige | #2772 |
| matched normal | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| anterior chamber | #2907 |
| test performed | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| expression adhesion | #3132 |
| rtpcr | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| symptom scores | #3181 |
| cell count | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| disease adolescent | #3694 |
| vegf mrna | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| microscopy | #3992 |
| chemokines | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| α induced | #4193 |
| papillary | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| nitrogen dioxide | #5023 |
| months treatment | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| epithelium | #5224 |
| thirtysix patients | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| grades | #5747 |
| th2 cells | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| linked immunosorbent | #6618 |
| glucocorticoids humans | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| humans japan | #6704 |
| months compared | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| 3 6 | #9098 |
| complaints | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| stained | #18391 |
| alkylating | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
रिपोर्ट चलाएं | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| के लिए जाना जाता है Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| के लिए जाना जाता है Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| के लिए जाना जाता है Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| के लिए जाना जाता है Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| के लिए जाना जाता है Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| के लिए जाना जाता है Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| के लिए जाना जाता है Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| के लिए जाना जाता है Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| के लिए जाना जाता है Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| के लिए जाना जाता है Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| के लिए जाना जाता है Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| के लिए जाना जाता है Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| के लिए जाना जाता है Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| के लिए जाना जाता है Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
के लिए प्रमुख लोग Allergic Conjunctivitis
दुनिया में शीर्ष kols
एक खोज वाक्यांश का चयन करें allergic conjunctivitis , allergic conjunctivitis asthma , allergic conjunctivitis mice , allergic conjunctivitis children , allergic conjunctivitis patients
Hiroshi Fujishima:विशेषज्ञ प्रभाव
जिसके लिए अवधारणाएंHiroshi Fujishimaप्रत्यक्ष प्रभाव है:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:कोल इम्पैक्ट
अन्य लेखकों के काम से संबंधित अवधारणाएं जिनके लिएfor which Hiroshi Fujishima प्रभाव है:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
क्या यह आपकी प्रोफ़ाइल है? अपनी प्रोफ़ाइल का दावा करें यूआरएल कॉपी करें अपनी प्रोफ़ाइल के लिए लिंक एम्बेड करें |